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1. Introduction 
Cancer is a leading cause of death in both more and less economically developed 
countries; the burden is expected to grow worldwide due to the growth and aging of 
the population, particularly in less developed countries, in which about 82% of the 
world's population resides. The adoption of lifestyle behaviors that are known to 
increase cancer risk, such as smoking, poor diet, physical inactivity, and reproductive 
changes (including lower parity and later age at first birth), have further increased the 
cancer burden in less economically developed countries.(Torre et al, 2015) Advances 
in treatment have led to improved survival of patients with cancer, but have also 
increased morbidity and mortality due to treatment side effects.(DeSantis et al, 2014; 
Ferlay et al, 2013)  Cardiovascular diseases (CVDs) are one of the most frequent of 
these side effects, and there is a growing concern that they may lead to premature 
morbidity and death among cancer survivors. This may be the result of cardiotoxicity, 
which involves direct effects of the cancer treatment on heart function and structure, 
or may be due to accelerated development of CVD, especially in the presence of 
traditional cardiovascular risk factors.(Armstrong et al, 2013) Patients with cancer can 
experience adverse cardiovascular events secondary to the malignant process itself or 
its treatment. They might also have underlying cardiovascular illness, the 
consequences of which are often exacerbated by the stress of the tumour growth or 
its treatment. With the advent of new treatments and subsequent prolonged survival 
time, late effects of cancer treatment can become clinically evident decades after 
completion of therapy. The heart's extensive energy reserve and its ability to 
compensate for reduced function add to the complexity of diagnosis and timely 
initiation of therapy. Additionally, modern oncological treatment regimens often 
incorporate multiple agents whose deleterious cardiac effects might be additive or 
synergistic. Treatment-related impairment of cardiac contractility can be either 
transient or irreversible. Furthermore, cancer treatment is associated with life-
threatening arrhythmia, ischaemia, infarction, and damage to cardiac valves, the 
conduction system, or the pericardium. Awareness of these processes has gained 
prominence with the arrival of strategies to monitor and to prevent or to mitigate the 
effects of cardiovascular damage. A greater understanding of the mechanisms of 
injury can prolong the lives of those cured of their malignancy, but left with 
potentially devastating cardiac sequelae.(Ewer & Ewer, 2015) 
Although the field of cardio-oncology has received increasing attention in recent 
years, many aspects of both radiation-induced and cancer drug–induced CVD are still 
to be fully elucidated. Furthermore, the inability to predict the long-term 
consequences of cancer treatment–associated cardiovascular side effects leads to 
under- or overdiagnosis of CVD, sometimes resulting in the failure to prevent adverse 
events and sometimes to inappropriate interruption of a potentially lifesaving cancer 
treatment. 
 
 
 
In general, the cardiovascular complications of cancer therapy can 
be divided into nine main categories, which are discussed in this 
document: 
1. myocardial dysfunction and heart failure (HF); 
2. coronary artery disease (CAD); 
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3. valvular disease; 
4. arrhythmias, especially those induced by QT-prolonging drugs; 
5. arterial hypertension; 
6. thromboembolic disease; 
7. peripheral vascular disease and stroke; 
8. pulmonary hypertension and 
9. pericardial complications. 
 
The challenge for the cardiovascular specialist is to balance the need for life-saving 
cancer treatment with the assessment of risk from cancer drug-associated 
cardiovascular side effects to prevent long-term damage. This review discusses 
concepts for timely diagnosis, intervention, and surveillance of cancer patients 
undergoing treatment, and provides approaches to clinical uncertainties. 
 
 
 
 
 
 
Figure 1 Depiction of the fundamental differences between non-reversible damage (type I) and reversible 
dysfunction (type II) (Suter & Ewer, 2013) 
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(Ewer et al, 2011; Force et al, 2007) 
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2. Non-reversible or reversible: a cardinal 
distinction 
 
Historically, non-reversible cardiovascular side effects that eventually led to 
progressive cardiac disease were the consequence of some oncologic therapies; a 
prime example being anthracycline induced cardiotoxicity leading to progressive 
systolic heart failure.(Gianni et al, 2008) With the introduction of new cancer drugs, 
such as signaling inhibitors, a new phenomenon has been observed; cardiac 
dysfunction that resolves for most patients over time. In an effort to classify 
cardiotoxicity of cancer drugs,(Ewer et al, 2005) proposed a system to identify drugs 
that have the potential to cause irreversible damage (Type I) vs. drugs that 
predominantly induce reversible dysfunction (Type II)  (figure 1).   
 
(Suter & Ewer, 2013) 
 
However, this classification system does have limitations; for example, trastuzumab, a 
Type II drug, can trigger irreversible cardiac damage in patients with severe 
preexisting cardiac disease, or potentiate anthracycline Type I cardiotoxicity(Sawyer 
et al, 2002). For cardiovascular side effects from other modern cancer therapeutics, 
such as angiogenesis inhibitors-induced arterial hypertension and nephrotoxicity, the 
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reversibility remains unknown.
 
 
(de Azambuja et al, 2009; Slamon et al, 2001; Smith et al, 2010; Swain et al, 2003; Von Hoff et al, 1979) 
 
3. Animal models on clinical trials 
Animals have been used by humans for centuries to understand their own biology. In 
cardiovascular research, animal models have allowed the study of cardiovascular 
disease in the early stages, as well as the investigation of the mechanisms of the 
pathogenesis of cardiovascular disease and the effects of drug intervention. The aim 
of these studies is to provide clear concepts for selected investigations in humans. An 
ideal animal model for any cardiovascular disease in humans should have five 
characteristics: (i) mimic the human disease, (ii) allow studies in chronic, stable 
disease, (iii) produce symptoms which are predictable and controllable, (iv) satisfy 
economical, technical and animal welfare considerations, and (v) allow measurement 
of relevant cardiac, biochemical and haemodynamic parameters. 
Animal species examined in detail as models of this cardiac toxicity include the 
rabbit, the normotensive and spontaneously hypertensive rat, the mouse, the pig, and 
the dog. The advantages and disadvantages of these animal models differ according to 
species: small animals can be used for comparative investigations, which may be 
available only in limited amounts, while large animals can be used for studies in 
which evaluation of cardiac function are to be made.  Among the various animals 
examined, the spontaneously hypertensive rat and the beagle dog are considered the 
most suitable small and large animal models, respectively, because of the 
reproducibility of the lesions induced by anthracyclines in the two species. A variety 
of pharmacologic agents has been tested for cardioprotective activity. The most 
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successful of these agents are those that function as antioxidants, because they either 
scavenge reactive oxygen species or prevent their formation. The most clinically 
useful of these agents is ICRF-187 (dexrazoxane), which has been found to be 
cardioprotective in all animal models. These whole animal studies enable repeated 
administration of chemotherapeutic agents, mimicking chronic cardiotoxicity in 
clinical practice. 
 
   3.1  Mice as animal models  
Cardiovascular diseases are common causes of morbidity and mortality in developed 
countries, and coronary heart disease is a relevant cause of congestive heart failure, 
which is frequently secondary to myocardial infarction (MI). Different species have 
been used to reproduce MI models, but in recent years mice have become the animals 
of choice for the analysis of several diseases, because of their short life cycle and the 
possibility of genetic manipulation(Acton et al, 2006). However, the dimensions of 
the mouse heart, with the left ventricular wall being thinner than 1 mm, represent a 
challenge for image acquisition and analysis that requires expensive equipment 
capable of obtaining high-resolution images and established expertise(Ratering et al, 
2010).  As a consequence, the procedures to measure myocardial tissue damage have 
some limitations. Measurements of the MI size with transmission microscopy and 
triphenyltetrazolium chloride staining can be performed only post mortem, and these 
techniques are not useful for longitudinal studies of the infarct area or to predict 
benefits of therapy (Saraste et al, 2009). There is therefore great interest in developing 
a non-invasive method for evaluation of infarct size in living mice, to improve our 
knowledge of metabolic and functional changes related to MI and the efficacy of 
interventional, pharmacological or molecular therapies. In vivo techniques currently 
used for infarct size delineation, such as echocardiography, X-ray computed 
tomography (CT), magnetic resonance (MR) and radionuclide imaging procedures, all 
have inherent advantages and limitations (Gargiulo et al, 2012). Echocardiography 
may be used serially to assess changes of cardiac structure, quantify ventricular 
function and detect non-perfused myocardium (Scherrer-Crosbie et al, 1999). 
However, this methodology is strongly operator dependent and does not provide 
information about glycolytic metabolism and myocardial viability (Ferro et al, 2007). 
Computed tomography allows an accurate evaluation of morphology (Nahrendorf et 
al, 2007). Disadvantages of CT include the use of ionizing radiation and the limited 
spatial resolution achievable in vivo, related to the radiation dose administered to the 
animals. Magnetic resonance imaging has the advantage of providing high tissue 
contrast and functional parameters, with the limitations of high cost and restricted 
availability (Vogel-Claussen et al, 2006).  
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   3.2  Rats as animal modes 
Most recent studies regarding central cardiac control have been conducted in the rat. 
A large amount of data already exists regarding neural mechanisms controlling heart 
rate in this species. Heart rate is a direct measure of autonomic outflow to the sino-
atrial node. Since neural influences on this pacemaker region and on the ventricular 
myocardium may differ (Braga et al, 2007; Nalivaiko et al, 2004),  it becomes evident 
that neurally induced chronotropic effects cannot be used as a general indicator of 
cardiac autonomic influences. The most commonly used ventricular indices are those 
reflecting cardiac inotropic state: the maximal left ventricular pressure (LVPmax) and 
the velocity of its rise (LVdP/dt). Methods of their assessment are invasive and 
technically demanding, especially in small mammals. The majority of studies of 
contractile function in the rat heart have been performed in vitro, in perfused hearts 
and in isolated papillary muscles or in fragments of myocardium (Piuhola et al, 2003; 
Vornanen, 1992). 
Left ventricular dP/dt depends on many parameters, including intrinsic (heart rate, 
preload, afterload, coronary perfusion) and extrinsic parameters (sympathetic and 
vagal neural influences, and humoral effects). This complex dependence between 
variables, where alteration in one can lead to changes in several others, makes the 
study of ventricular contractility a challenging task. To overcome this difficulty, 
numerous attempts have been made to find contractility indices that are independent 
of heart rate, preload and afterload (Connelly et al, 2006).  
   3.2  Rabbits as animal models 
There are several models of cardiac hypertrophy employed in experimental animals to 
generate the features of a failing heart, these have been reviewed elsewhere.  A 
common approach is to simulate a myocardial infarction by ligation of a coronary 
artery via an operative procedure. The infarct is allowed to heal and the remaining 
myocardium hypertrophies to compensate for the loss. The myocardial infarction 
model in the rabbit has been extensively characterized. This model demonstrates 
many features of clinical heart failure, including impairment of left ventricular 
ejection fraction (Pye & Cobbe, 1996), compensatory hypertrophy (Ng et al, 
1998)  and neuroendocrine activation.  
 
   3.3 Pig as animal model 
Transgenic technology has potentially solved many of the immunological difficulties 
of using pig organs to support life in the human recipient. Nevertheless, other 
problems still remain. Knowledge of cardiac anatomy of the pig (Sus scrofa) is 
limited despite the general acceptance in the literature that it is similar to that of man. 
A qualitative analysis of porcine and human cardiac anatomy was achieved by gross 
examination and dissection of hearts with macrophotography. The porcine organ had 
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a classic 'Valentine heart' shape, reflecting its location within the thorax and to the 
orientation of the pig's body (unguligrade stance). The human heart, in contrast, was 
trapezoidal in silhouette, reflecting man's orthograde posture (Sahni et al, 2008). The 
morphologically right atrium of the pig was characterised by the tubular shape of its 
appendage (a feature observed on the left in the human heart). The porcine superior 
and inferior caval veins opened into the atrium at right angles to one another, whereas 
in man the orifices were directly in line. A prominent left azygous vein (comparable 
to the much reduced left superior caval or oblique vein in man) entered on the left side 
of the pig heart and drained via the coronary sinus. The porcine left atrium received 
only 2 pulmonary veins, whereas 4 orifices were generally observed in man. The 
sweep between the inlet and outlet components of the porcine right ventricle was less 
marked than in man, and a prominent muscular moderator band was situated in a 
much higher position within the porcine right ventricle compared with that of man. 
The apical components of both porcine ventricles possessed very coarse 
trabeculations, much broader than those observed in the human ventricles. In general, 
aortic-mitral fibrous continuity was reduced in the outlet component of the porcine 
left ventricle, with approximately two-thirds of the aortic valve being supported by 
left ventricular musculature. Several potentially significant differences exist between 
porcine and human hearts. It is important that these differences are considered as the 
arguments continue concerning the use of transgenic pig hearts for 
xenotransplantation (Crick et al, 1998) 
 
   3.4  Dog as animal model 
 
Dog and human hearts share many characteristics on both the organ and cellular 
levels. Dog  heart rate, body weight, and heart weight are more comparable to humans 
than the heart rate, body weight, and heart weight of mice, rats, and rabbits. Due to 
their size, almost all in vivo techniques used to assess contractility of human hearts 
can be utilized in dogs. Housing and maintenance of dog models is considerably more 
expensive than small rodents and cats; therefore, this issue must be taken into 
consideration when long-term studies and disease models are being considered. One 
disadvantage, unique to canines, is obtaining the necessary approval for performing 
experiments in this species. 
Furthermore, the human population is heterogeneous with slight genetic variations; a 
property which is not reflected in the inbred laboratory mouse, rat, or rabbit strains. In 
that regard, it is suggested that mixed dog breeds such as mongrels are better suited 
for addressing this issue. This is supported by reports that various cardiac functions, 
parameters, properties, and response to stress vary depending on the mouse strains. 
Due to their size, pretty much all in vivo techniques used to assess contractility of 
human hearts can be utilized in canines. Beyond these characteristics, the 
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myocardium of canines and humans share many properties and similarities. The 
action potential duration of canine is only a little bit shorter than that of humans, 
much more comparable than the animal models discussed previously (canine APD90: 
~ 219 ms, human APD90: ~290 ms both measured in right ventricular papillary 
muscles at cycle length of 1000 ms and 37 °C). Furthermore, there is a high degree of 
resemblance between human and canine sino-atrial (SA) node activity and structure, 
purkinje fiber distribution, and activation sequence. Three separate surveys of the 
pharmaceutical industry revealed that canine was the most commonly used animal 
model for evaluation and determination of QT interval prolongation of novel 
compounds. For thoroughness purposes, we must point out that it is proposed that the 
“effective size” of the heart (third root of heart weight divided by spiral wave rotation 
period) determines ventricular fibrillation pattern. Based upon this analysis, it is 
argued that rabbits have a closer effective size to humans and hence more similar 
ventricular fibrillation patterns than either dogs or pigs. Nevertheless, the similarities 
of human and canine excitation processes and structure make canine a good animal 
model for studying cardiac electrophysiology as it relates to human health and 
disease. 
Despite the high degree of similarity between human and dog myocardium, some 
differences have been reported between these two species. Such differences include 
resting and exercise heart rates , kinetics of Ito current inactivation, its recovery, and 
molecular size of its corresponding ion channels, sensitivity to flecanideand 
transmural epicardial:endocardial expression levels of HERG ion channel(Milani-
Nejad & Janssen, 2014). 
4. CARDIOVASCULAR DISEASES AS SIDE EFFECT OF 
CARDIOTOXICITY 
4.1 Cardiac dysfunction and heart 
Failure 
Cardiac dysfunction and heart failure are among the most serious cardiovascular side 
effects of systemic cancer treatment. Conventional chemotherapeutics, such as 
anthracyclines, anti-metabolites, and cyclophosphamide, can induce permanent 
myocardial cell injury—albeit by diverse mechanisms—and by cardiac remodeling 
(Mann & Bristow, 2005).  Signalling inhibitors currently in use, like human epidermal 
growth factor receptor 2 (HER2/erbB2) and angiogenesis inhibitors, predominantly 
affect cardiac metabolism and contractile proteins, leading to transient contractile 
dysfunction. Understanding the mechanistic pathophysiology of cancer drug-
associated cardiac dysfunction is important to predict, treat, and prevent these side 
effects, although it can be challenging to identify the proper mechanism in individual 
patients. 
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4.2 Cardiovascular side effects beyond cardiac dysfunction 
4.2.1 Arterial hypertension 
 
Cancer drug-induced arterial hypertension is now recognized as an entity primarily 
associated with the use of angiogenesis inhibitors (Maitland et al, 2010).  On a dose-
dependent basis, these drugs can worsen pre-existing hypertension, or can cause de 
novo hypertension to develop. It is difficult to determine the true incidence of anti-
VEGF-induced hypertension since various methods of blood pressure measurement 
and definitions of hypertension have been used in trials. A recent meta-analysis of 
studies with bevacizumab reported an incidence of more than 23% for any grade 
hypertension, with almost 8% of patients experiencing severe hypertension(Ranpura 
et al, 2010).  The incidence of arterial hypertension associated with sunitinib and 
sorafenib appear similar, and patients with pre-existing hypertension or renal cell 
cancer have a higher risk (Wu et al, 2008; Zhu et al, 2009). 
Hypertension can occur at any time during treatment: acute complications include 
heart failure, proteinuria with renal thrombotic microangiopathy, intracerebral 
haemorrhage, and, infrequently, reversible posterior leukoencephalopathy (Maitland 
et al, 2010).  It is unclear if patients will encounter hypertension-induced long-term 
consequences, such as cardiac and renal remodelling. For most patients, the condition 
improves when angiogenesis inhibitor treatment is held or stopped altogether, but in 
some instances profound hypertension may persist and become life-threatening. 
Interestingly, in the case of sunitinib, a correlation has been demonstrated between 
oncologic efficacy and hypertension, suggesting that blood pressure increases may be 
a marker for efficacy rather than, or in addition to, a simple cardiac adverse event. 
Treatment of sunitinib-associated hypertension has not been shown to impair 
oncologic response, but further studies are needed. Such interactions further support 
the need for careful monitoring and clinical correlations between efficacy and 
adversity, and the need for a broad onco-cardiologic perspective. 
The mechanism of angiogenesis inhibitor-induced hypertension is not completely 
understood, but may be directly linked to the inhibition of VEGF-2 signalling (Chen 
& Cleck, 2009).  Vascular endothelial growth factor signalling is important for proper 
endothelial function and nitric oxide synthesis; inhibition impairs vasodilation (Ku et 
al, 1993). Other effects of VEGF inhibition may include induction of endothelial cell 
death and rarefaction of resistance vessels (Maitland et al, 2010).  Hypertension 
involves mechanisms similar to those of tumour destruction, and therefore may also 
be a marker for efficacy of angiogenesis inhibitors (Mir et al, 2009). 
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4.2.2 Vasospastic and thromboembolic ischaemia associated with anti-
cancer treatment 
Among agents associated with coronary artery spasm, the pyrimidine analogues 5-
fluorouracil (5-FU) and its oral pre-drug capecitabine are the most common (Kleiman 
et al, 1987; Stewart et al, 2010). Underlying coronary artery disease has been 
associated with an increased incidence of coronary artery spasm, although there are 
patients with normal coronaries that have had spasms while being treated with these 
drugs. Rhythm disturbances accompanying ischaemic events have been reported as 
well. Ischaemia most typically occurs after the second or third administration of these 
antimetabolites. Nitroglycerin and calcium-channel blockers are often effective for the 
treatment and prevention of ischaemia. In rare instances, progression to myocardial 
infarction has been reported. 
 
4.2.3 Thromboembolic events 
 
Patients with malignancies are in a hypercoagulable state and conventional 
chemotherapeutics, signalling inhibitors, and endocrine cancer therapies can further 
increase a patient's risk of experiencing a venous or arterial thromboembolic event 
(VTE and ATE, respectively)(Ay et al, 2010). For example, cisplatin was found to 
cause VTE in up to 18% of patients; a direct endothelial-toxic effect and changes in 
the coagulation system are likely responsible for this side effect (Moore et al, 2011). 
 Patients treated with bevacizumab also experienced a higher rate of thromboembolic 
events compared with patients treated with chemotherapy alone; elderly patients with 
cardiovascular risk factors were shown to have the highest rates of all(Nalluri et al, 
2008; Scappaticci et al, 2007). Similar risks for ATEs have been reported for sunitinib 
and sorafenib (Choueiri et al, 2010).  Increased incidences of thromboembolic events 
have also been found with hormonal therapy, such as tamoxifen, which is now an 
integral part of many breast cancer regimens (Freedman et al, 2011).  
Prophylactic anticoagulation is only recommended in high-risk cancer patients who 
are hospitalized or undergo surgery and in selected patients with multiple myeloma 
(Lyman et al, 2007). Several trials are currently investigating the potential role of 
prophylactic low molecular heparin. There are no clear guidelines for the prevention 
of ATEs in the setting of cancer therapy; only evidence-based guidelines used for 
patients without cancer should be used until studies are conducted. It is unknown 
whether cancer patients have an altered risk of coronary thrombosis after stenting. 
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4.2.4 Dysrhythmia and QT prolongation 
 
Rhythm disturbances associated with anti-cancer treatment are typically transient and 
not especially troubling. They occur most commonly as a consequence of metabolic 
changes and generally resolve after electrolyte homeostasis is re-established. 
Anthracyclines, for example, are associated with supraventricular arrhythmias and 
ventricular ectopy during and shortly after administration, a condition that usually 
resolves without sequelae after heart rate control. Similarly, taxanes can induce sinus 
bradycardia during treatment, but this is seldom severe and intervention is rarely 
warranted. Some rhythm disturbances are associated with structural changes within 
the heart, as may be seen with tumour invasion or as a manifestation of chronic 
anthracycline cardiomyopathy. 
QT prolongation is associated with a number of anti-cancer drugs and may constitute 
a significant problem. Many cancer patients have multiple comorbidities, including 
diarrhea- and vomiting-induced electrolyte disturbances, and concomitant medications 
such as psychotropic medications and anti-emetics that may further prolong the QT 
interval. Among specific anti-cancer treatments, arsenic trioxide, typically used to 
treat leucemia, has received considerable attention in this regard since it may prolong 
the QT interval in up to 40% of treated patients and has a significant risk of Torsades 
de Pontes (Soignet et al, 2001).  Several of the newer signalling inhibitors also 
prolong the QT interval, although Torsades is a relatively infrequent event. 
Vandetanib, an orally available multiple target TKI for the treatment of thyroid 
cancer, has been associated with a moderate risk of QT prolongation (Wells et al, 
2010). Nilotinib and dasatinib can also prolong the QT interval, although 
symptomatic manifestations were recorded in only a few patients (Kantarjian et al, 
2011).  In patients treated with lapatinib or sunitinib, QT prolongation was rarely 
observed.  
 
While cardiovascular side effects such as arterial hypertension, myocardial ischaemia, 
dysrhythmia, and thrombosis can be readily diagnosed, the assessment of cardiac 
dysfunction and its prognosis is more challenging. Most currently used methods 
assessing cardiac function cannot differentiate between irreversible (Type I) and 
reversible (Type II) cardiotoxicity, and may mislead physicians to stop potentially 
lifesaving cancer therapy unnecessarily. 
Historically, patients with anthracycline-induced cardiotoxicity were evaluated with 
right-ventricular endomyocardial biopsies; morphologic changes correlated with the 
cumulative dose applied and (to a limited extent) with the onset of heart failure 
(Mackay et al, 1994). However, correlation of biopsy scores with non-invasively 
assessed LVEFs was poor (Ewer et al, 1984). More recently, the predictive value of 
serial LVEF evaluation by either echocardiography or multiple gated acquisition 
(MUGA) scans in adult cancer patients was assessed in several studies. While some 
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investigators found an early drop in LVEF to be predictive for later onset of heart 
failure, others did not (Jensen et al, 2002; Mitani et al, 2003; Swain et al, 2003) 
 
 
 
5. EXPERIMENTAL DATA 
Advances in early cancer diagnosis and therapy have improved the survival statistics 
of individuals with cancer in the last few decades. Current data reported by the 
American Cancer Society shows that the 5-year relative survival rate in cancer 
patients is 68%, or 19% higher than three decades prior.1 In children, mortality rates 
have dropped by more than 50% in the period between 1975 and 2010.1 These 
increased survival rates are bringing attention to the long-term effects of 
chemotherapy in children and adults, and to how chemotherapy affects organ systems, 
in our case the cardiovascular system.  
 
  Drugs causes cardiotoxicity in animal models 
 Animal 
specie 
Class/Drug Echocardiography 
results 
 Doses Time of 
treatme
nt 
Citatio
n 
1. Rats 
doxorubicin 
(DOX) - 
Anthracyclin
e 
Franctional 
Shortening -13,9% 
(average change in 
FS = 0.20) 
 18 mg/kg 12 days (Ferna
ndez-
Ferna
ndez 
et al, 
2014) 
2. Mice Imatinib 
Mesylate 
LVPW (mm) * 
Young 0.65± 0.02 
Old 0,78± 0.12 
 200 
mg/kg/day 
5 weeks 
 
 
 
(Mah
arsy 
et al, 
2014) 
3. Rats ramipril and 
darbepoetin 
(erythropoi
etin 
hormones)  
in 
doxorubicin
-induced 
cardiotoxici
ty 
LVEF**, % DOX + 
RAM + DP - 63.43 ± 
3.66b  
LVFS***, % DOX + 
RAM + DP - 30.71 ± 
2.67b 
 2.5 mg/kg i.v. 
DOX + 1 mg/kg 
p.o. ramipril + 
10 μ/ kg i.p. 
darbepoetin 
alfa 
 
 
 
4 weeks 
 
 
 
 
 
 
 
 
(Ozka
nlar 
et al, 
2014) 
4. 
 
 
 
 
Wistar 
Rats 
Doxorubicin 
and cardiac 
function 
improveme
nt after 
1.EF (%) – 60.8 
(13), FS (%) – 33.4 
(9.2) 
2. EF (%)-63.6 (4.1), 
FS (%) – 35.2 (3.5) 
 1.Dox 5mg/kg 
2.Dox 
5mg/kg+ 
C.sinensis 
100/kg 
4 weeks (Olive
ira et 
al, 
2013) 
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stem cell 
therapy and 
flavonoid 
extract 
treatment 
3.EF (%) – 
73.6(1.9), FS (%) – 
43.6(1.6) 
 
  
3.Dox 5mg/kg 
+MSC 
5. Wistar 
Rats 
Pamidronat
e 
Attenuates 
Oxidative 
Stress 
in Acute 
Doxorubicin
-Induced 
Cardiotoxici
ty 
 
PWRT ˣ 
1. 0,36 
2. 0,51 
3. 0,41 
 
LVDD+ 
1. 7,14 
2. 6,20 
3. 6,77 
 1.Pamidronate 
3mg/kg 
2. DOX 
20mg/kg 
3.DOX 
20mg/kg + 
pamidronate 
3mg/kg 
3 days (Carv
alho 
et al, 
2016) 
6
. 
Chinc
hilla 
rabbit 
Daunorubici
n 
LV fractional 
shortening lower 
than 20 % 
  DAU 3mg/kg 
i.v 
10 
weeks 
(Lenc
ova-
Popel
ova 
et al, 
2014) 
7
. 
Wistar 
rats 
(alpha) 
tocopherol 
(vitamin E) 
induces car
diotoxicity 
 
Ao (mm) ₓ 
Control 3.8 + 0.2 
E 3.4 + 0.4 
PWT (mm) 
Control 1.64 + 0.26 
E 1.42 + 0.14 
LVD (mm) 
Control 7.37 + 0.62 
E 7.22 + 0.41 
 250 mg a-
tocopherol/kg 
body wt/day 
orally 
7 weeks (Nasci
ment
o et 
al, 
2011) 
8
. 
WT and  
GSTP 
null 
mice 
Cyclophosp
hamide 
LVIDD : Null, 1h 
3.39±0.32 
EF : WT, 1h 70.4±3.4 
Null, 1h 72.2±3.4 
     : Null, 4h 11.91±1.00 
 300 mg/kg  4 hours (Conk
lin et 
al, 
2015) 
9
. 
wild-
type 
(WT) 
mice and 
Mrp1 
null 
(Mrp1
−/−
) 
littermat
es 
Doxorubicin FS : 20.0%–24.3% 
Mrp1 versus 
23.7%–29.5% WT  
Protocol A  
EF : 41.5%–48.4% 
Mrp1 versus 
47.7%–56.7% WT 
Protocol B 
 protocol A 
total dose: 18 
mg/kg 
protocol B 
total dose: 20 
mg/kg 
5 weeks (Zhan
g et 
al, 
2015
b) 
10
. 
Mice N-Acetyl 
Cysteine 
Amide in the 
Prevention of 
Doxorubicin 
and 
Trastuzumab
–Mediated 
Cardiac 
LVEF:  
DOX from 73±4% 
to 43±2% 
 DOX+TRZ from 
72±3% to 32±2% 
NACA +/or DOX + 
TRZ 62±3% and 
55±3% 
 injection: (i) 0.9% 
saline; (ii) NACA 
(250mg/kg); (iii) 
DOX (20mg/kg); (iv) 
TRZ (10mg/kg); (v) 
DOX (20mg/kg) + 
TRZ (10mg/kg); (vi) 
NACA (250mg/kg) + 
DOX (20mg/kg); (vii) 
NACA (250mg/kg) + 
TRZ (10mg/kg); and 
10 days (Goya
l et al, 
2016) 
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Dysfunction 
 
(viii) NACA 
(250mg/kg) + DOX 
(20mg/kg) + TRZ 
(10mg/kg) 
11
. 
Rats Angiotensin 
Type I 
Receptor 
Antagonist, 
Fimasartan, 
Prevents 
Doxorubicin
-induced 
Cardiotoxici
ty 
 
LV EF (%) : 
Control 74.6 ± 3.7 
Dox-only 54.6 ± 8.4 
Low-fima 67.9 ± 
5.3 
High-fima 71.4 ± 
6.3 
 DOX : 500 mg 
per m2 
Fimasartan 
(low - fima) : 5 
mg/kg  
Fimasartan(hi
gh - fima) : 
10mg/kg 
8 weeks (Chan
g et 
al, 
2015) 
12
. 
Mice Renin 
angiotensin 
system 
antagonists 
in the 
prevention 
of 
doxorubicin 
and 
trastuzuma
b induced 
cardiotoxici
ty 
LVFS ii : from 
51 ± 1% at baseline 
to 32 ± 2% 
Bii : 45 ± 1% 
Cii : 38 ± 1% 
Dii : 37 ± 2% 
 
LVFS iii : from 
52 ± 2% at baseline 
to 26 ± 2% 
Biii : 40 ± 1% 
Ciii : 32 ± 1% 
Diii : 33 ± 2% 
 (A) placebo  
(B)Aliskiren: 
(50 mg/kg) 
(C)Perindopril:
(3 mg/kg) 
(D)Valsartan:(
10 mg/kg) 
+ 
(i) TRZ 
4 mg/kg 
weekly (i.p.) 
(ii) DOX 
4 mg/kg 
weekly, i.p 
(iii) DOX+TRZ  
13 
weeks 
(Akol
kar et 
al, 
2015) 
13
. 
Rats Ginsenoside Rg3 
antagonizes 
adriamycin-
induced 
cardiotoxicity by 
improving 
endothelial 
dysfunction 
 
EF Rg3 40mg/kg : 
85,45% 
FS Rg3 40mg/kg : 
56.04% 
 Adriamycin 
(doxorubicin 
hydrochloride) : 
15mg/kg 
Ginsenoside Rg3 
(ADM + 10/20/40 
mg/kg daily) 
14 days (Wan
g et 
al, 
2015) 
14
. 
pregna
nt 
Wistar 
rats at  
Cardiotoxici
ty in 
Response to 
Maternal 
Doxorubicin 
Treatment 
 
FS 20mg/kg  
decreased by 
 5–10%  20-mg  
The umbilical systolic 
peak velocity and the 
ductus venosus 
Doppler 
measurements did 
not show significant 
differences between 
the groups 
 10 or 20 mg/kg 
i.v. doxorubicin 
to pregnant 
Wistar rats at 
day 18 of 
pregnancy 
48 
hours  
(Gziri 
et al, 
2013) 
15
. 
Wistar
Rats 
Bortezomib 
induced 
cardiotoxici
ty 
 
EF 40% 
FS 34% 
 Bortezomib 
0.2mg/kg 
three 
times/week 
3 weeks (Nowi
s et 
al, 
2010) 
16
. 
Sprag Atorvastatin EF % :  E1 (10 6 (Zhan
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ue-
Dawle
y rats 
Ameliorates 
Radiation-
Induced 
Cardiac 
Fibrosis 
 
Control 80.13 ±  7.32 
Radiation only 64.47 
 ± 11.56 
E1 72.75  ±  6.91 
E2 72.92  ± 10.88 
E3 74.92  ± 10.88 
E4 80.47 ±   4.02 
 
FS %  
Control 44.17  ±  5.99 
Radiation only 33.13 
±  3.72 
E1 38.24 ±  6.84 
E2 39.10 ±  3.61 
E3 39.93 ±  6.39 
E4 41.93 ±   6.19 
mg/kg/day) and 
E2 (20 
mg/kg/day)  
atorvastatin and 
radiation  
E3 (10 
mg/kg/day) and 
E4 (20 
mg/kg/day) 
atorvastatin 
from 3 months 
before 
irradiation to 
week 12 after 
irradiation 
months g et 
al, 
2015a
) 
17
. 
C57BL/
6 
Mice  
NC-6300 
reduces 
the cardiotox
icity of 
epirubicin 
 
EF %  
EPI : 48% 
NC-6300 : 70% 
 
FS% 
EPI : 25% 
NC-6300 : 40% 
 NC-6300 (10, 15 
mg/kg) 
Epirubicin (10 
mg/kg) 
12 
weeks 
(Taka
hashi 
et al, 
2013) 
18
. 
Beagle 
dogs 
cardiotoxicit
y of 
minoxidil  
 
EF %  
Control : 65% 
0,5 minoxidil: 84% 
2 minoxidil: 89% 
  0.5 or 2 mg/kg 
minoxidil 
48 
hours 
(Hant
on et 
al, 
2004) 
19
. 
Spragu
e 
Dawle
y rats 
testosterone 
and 
dehydroepia
ndrosterone 
induce 
cardiotoxicity 
Control EF% : 67.80 ±   
1.68, FS%: 33.00±    
0.70 
DHEA EF%: 64.00 ±   
1.89, FS%: 32.40 ±   
0.81 
T 10 mg/100 g EF%: 
76.33±  4.33, FS%: 
42.00 ± 3.05 
 
T 30 mg/100 g EF%: 
70.60 ±  1.88, FS%: 
36.20 ±  1.15 
T 100 mg/100 g EF% : 
72.25 ±  1.43, FS% : 
36.00 ±  0.81 
 
 Testosterone 
(10, 30, and 100 
mg/100 g body 
weight) 
DHEA (10 
mg/100 g body 
weight) 
3 
months 
(Emer 
et al, 
2016) 
20
. 
Rats Cardioprotec
tive effects 
of 
rosuvastatin 
in Dox 
induced 
cardiotoxicity 
 
FS% 
I : 50.0 ± 0.7 
II : 39.7 ± 1.7 
III : 40.5 ± 3.0 
IV : 42.6 ± 2.6 
V : 37.9 ± 2.2 
VI : 34.9 ± 2.8 
 
LVESD (mm) 
I : 3.6 ± 0.09 
II : 4.5 ± 0.09 
 Croup I control 
Group II: 
doxorubicin  1.25 
mg/kg Group III: 
doxorubicin + 
rosuvastatin 2 
mg/kg/day, 
Group 
IV:doxorubicin + 
rosuvastatin 10 
mg/kg/day, 
GroupV:doxorubi
8 weeks (Kim 
et al, 
2012) 
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III : 4.6 ± 0.22 
IV : 4.2 ± 0.25 
V : 4.6 ± 0.24 
VI : 4.9 ± 0.23 
cin + carvedilol 5 
mg/kg/day, 
Group 
VI:doxorubicin + 
carvedilol 10 
mg/kg/day 
21
. 
Wistar 
rats 
Oleuropein 
prevents 
doxorubicin
-induced 
cardiomyop
athy 
 
Control: FS%69.6 
(1.4), PWTdmm 2.8 
(0.1) 
OLEU-1: FS%67.4 
(2.3), PWTdmm 2.7 
(0.0) 
OLEU-2: FS%69.1 
(4.2), PWTdmm 2.7 
(0.1) 
DXR: FS%3.5 (2.5), 
PWTdmm 1.6 (0.1) 
OLEU-1-DXR: 
FS%67.1 (1.6), 
PWTdmm 2.4 (0.2) 
OLEU-2-DXR: 
FS%68.1 (2.0), 
PWTdmm 2.5 (0.4) 
 Control group: 
2 ml of normal 
saline 
OLEU-1: 
1000mg/kg 
oleuropein 
OLEU-2: 
2000mg/kg 
oleuropein 
DXR group: 
8mg/kg DXR 
 
2 weeks (Andr
eado
u et 
al, 
2014) 
22
. 
Spragu
e–
Dawle
y rats 
telmisartan 
in limiting 
the cardiotox
ic effect of 
daunorubicin 
 
Control EF%: 83.4 ± 
3.47, FS%: 47.5 ± 
3.24 
DNR EF%: 49.44±  
7.02, FS%: 22.3±  
3.84 
TELM EF%: 64.87 ± 
8.23, FS%: 32.63 ± 
6.3 
 Control 
DNR: 3 
mg/kg/day 
every other day 
Telm: (10 
mg/kg/day 
 
12 days (Aroz
al et 
al, 
2010) 
23
. 
Fisher 
344 
rats 
metronomic 
treatment 
with 
cyclophosph
amide 
DOX LVEF 12% 
decrease 
CPA LVEF 2% 
decrease 
 Control 
CPA 150 
mg/kg 
DOX  12 
mg/kg 
 
6 weeks (Todo
rova 
et al, 
2011) 
24
. 
C57Bl/
6 mice 
Probucol 
against 
anthracyclin
e and 
trastuzuma
b-
mediated ca
rdiotoxicity 
 
Control FS%: 53 6 2, 
LVEDDmm: 3.2±  0.1 
DOX FS%: 42 ±  2, 
LVEDDmm: 3.8±   0.2 
TRZ FS%: 52±  3, 
LVEDDmm: 3.2± 0.1 
DOX + TRZ FS%: 35 ± 
3, LVEDDmm: 4.1 ±  
0.2 
PROB + DOX FS%: 47 
±  2, LVEDDmm: 3.5±  
0.1 
PROB + DOX + TRZ 
FS%:44±2, 
LVEDDmm: 3.6±  0.1 
 Control 0.9% 
saline  
Prob 15mg/kg 
Dox 20 mg/kg 
Trz 10 mg/kg 
24 days (Walk
er et 
al, 
2011) 
25
. 
C57BL/
6J 
mice 
Anti-Fas 
Gene 
Therapy 
Control FS% : 40% 
LacZ gene FS%: 
 DOX 15 mg/kg 
sFas gene or 
2 weeks (Miya
ta et 
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Prevents 
Doxorubicin-
Induced 
Acute 
Cardiotoxicit
y 
 
28% LacZ gene al, 
2010) 
26
. 
Wistar 
rats 
Crocin 
treatment 
prevents 
doxorubicin
-
induced car
diotoxicity 
 
Control EF%:70.19 
± 1.71, FS%:33.31 ± 
1.24  
DOX EF%:50.03 ± 
5.10, FS%:21.16 ± 
2.88 
CRO 20 EF%:65.50 
± 1.50, FS%:29.94 ± 
1.02 
CRO 40 EF%:68.07 
± 3.01,FS%:31.98 ± 
2.11 
 
 
 Group 1 
:Control 
Croup 2:DOX 
2mg/kg/48 h 
Group 3:DOX 
2mg/kg+CRO 
20 mg/kg/24 h 
Group 4: DOX 
2mg/kg + CRO 
40mg/kg 
20 days (Raz
marai
i et al, 
2016) 
27
. 
Wistar 
albino 
rats 
Cardioprote
ctive effect 
of 
metformin 
against 
doxorubicin
 cardiotoxicit
y 
 
Control EF%: 
77.76±4.95, FS%: 
41.32±4.47 
DOX 
EF%:60.92±9.25, 
FS%:28.76±6.16 
MET EF%: 
75.71±6.13, 
FS%:39.60±5.57 
DOX+MET 
EF%:71.62±5.40, 
FS%:36.03±4.31 
 
 
 
 Control: saline 
twice a week 
DOX: 4mg/kg 
twice a week 
Met: 
250mg/kg/day 
2 weeks (Argu
n et 
al, 
2016) 
28
. 
Spragu
e-
Dawle
y rats 
Anandamide 
in an acute 
doxorubicin c
ardiotoxicity 
 
CON+SAL FT(ms): 58 
+ 3 , ET(ms): 63 + 3  
CON+DOX FT(ms): 78 
+ 5, ET(ms): 60 + 3 
DOX+ANAN FT (ms): 
67 + 3, ET(ms): 63 + 3 
 Group1 : ANAN 
+ DOX (30 mg 
kg   Anan to 
10mg kg⁻ⁱ) 
Group2: 
CON+DOX 
Group3: 
ANAN+Saline 
Group4: 
ANAN+DOX 
5 days (Hydo
ck et 
al, 
2009) 
29 Spragu
e-
Dawley 
rats 
Cardioprote
ctive effect 
of 
dexrazoxan
e 
 
MI EF%: 41.2± 
11.5, FS%:17.9± 6.3 
MI+DZR EF%: 52.0± 
9.8, FS%:23.6± 5.7 
DZR EF%: 77.0± 
4.0, FS%:40.9± 3.6 
 DZR group: 
125mg/kg 
4 weeks (Zhou 
et al, 
2011) 
30
. 
Wistar 
albino 
Resveratrol 
treatment 
Group1 EF%:63.8±  Group1: 
saline+doxorubi
7 weeks (Tatli
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rats protects 
against 
doxorubicin-
induced cardi
otoxicity 
 
2.6, FS%: 23.6± 1.9 
Group2 EF%:75.4± 
1.5, FS%:37.2± 3.4 
cin (DOX; 20 
mg/kg) 
Group2: RVT 
(10 
mg/kg)+DOX 
(20mg/kg) 
dede 
et al, 
2009) 
 
*LVPW, left ventricular posterior wall (diastole) 
** LVEF: Left ventricular ejection fraction 
*** LVFS: Left ventricular fractional shortening 
ˣ PWRT: left ventricular posterior wall relative thickness (2xposterior wall thickness/LVDD) 
+ LVDD: left ventricular diastolic diameter 
ₓ PWT: posterior wall thickness 
 Vcf, velocity circumferential fiber shortening (circ/s) 
5.1 Doxorubicin (DOX) - Anthracycline induced cardiotoxicity 
DOX-treated animals showed a significant (p<0.001) decrease between days 1 and 11, 
with an average FS change of −13.9%; whereas control animals did not undergo a 
significant change in fractional shortening (average change in FS = 0.20%) 
5.2 Imatinib Mesylate induced cardiotoxicity 
 Mice treated with imatinib showed a reduced LV posterior wall thickness which was 
further confirmed by histological examination 
5.3 Ramipril and darbepoetin (erythropoietin hormones)  in doxorubicin-
induced cardiotoxicity 
Forty 6-month-old Sprague–Dawley male rats were divided into 5 groups. The 
Control group had no medication. The DOX group received 2.5 mg/kg i.v. DOX 
hydrochloride (Adriblastina, Pfizer Inc.) from tail veins weekly for 3w. The DOX + 
RAM group received 2.5 mg/kg i.v. DOX plus 1 mg/kg p.o. ramipril (Delix, Pharma 
Vision) via gavage daily for 4w. The DOX + DP group received 2.5 mg/kg i.v. DOX 
plus 10 μ/ kg i.p. darbepoetin alfa (Aranesp, Amgen Inc.) weekly for 3w. The DOX + 
RAM + DP group had 2.5 mg/kg i.v. DOX plus the same amount and duration of 
ramipril and darbepoetin. Sampling and measurement were obtained at the 4th week. 
The animals, induced cardiotoxicity, and have shown anaemia, systolic dysfunction 
and repolarization abnormalities based on the results of haematology, 
echocardiography and ECG, respectively. It is concluded that anaemia and systolic 
dysfunction are the main problems of DOX cardiotoxicity and solving these problems 
should be the main goals of the therapy. Therefore, administration of weekly DP 
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injection and daily oral RAM together may have significant potentials to improve 
heart conduction abnormalities and anaemia but not the systolic dysfunction caused 
by DOX toxicity during same period of treatments. 
5.4 Doxorubicin and cardiac function improvement after stem cell 
therapy and flavonoid extract treatment  
Different therapy strategies, such as flavonoid plant extracts and stem cells, have been 
investigated to improve heart function in toxic cardiomyopathy. This work aimed to 
assess early cardiac function improvement after treatments with either flavonoid 
extract from Camellia sinensis or mesenchymal stem cells in Dox cardiotoxicity using 
strain echocardiography. Twenty Wistar rats were randomly assigned to four groups. 
They received water (control, Dox, Dox + stem cells) or 100 mg/kg C. sinensis extract 
(Dox + C. sinensis) via gavage, daily, for four weeks. Animals also received saline 
(control) or 5 mg/kg doxorubicin (Dox, Dox + C. sinensis, Dox + stem cells) via 
intraperitoneal injection, weekly, for four weeks. Stem cells were injected (3 × 
10
6
 cells) through tail vein prior the beginning of the experiment (Dox + stem cells). 
Animals were randomly categorized into four groups: control (distilled water orally 
(P.O.) daily; saline intraperitoneal (I.P.) weekly); Dox (distilled water P.O. daily; 5 
mg/kg Dox I.P. weekly); Dox + C. sinensis(100 mg/kg C. sinensis extract P.O. daily; 
5 mg/kg Dox I.P. weekly); Dox + MSC (distilled water P.O. daily; 5 mg/kg Dox IP 
weekly; MSC via intravenous injection). Distilled water and plant extract (1 ml) were 
given through gavage procedure, which was first performed three days prior, the 
beginning of the experiment (first Dox injection). The C. sinensis extract used 
contains polyphenols > 80%, catechins > 80%, epigallocatechin > 45%, and caffeine 
< 1% detected by high performance liquid chromatography analysis as informed by 
the manufacture. The MSCs were isolated from adipose tissue of Lewis LEW-Tg 
(EGFP) F455.5/Rrrc rats, which were obtained from the Rat Resource and Research 
Center (Missouri, USA). 
Echocardiographic indices 
Echocardiography examination showed left ventricular dysfunction in Dox group, 
compared to control (p<0.05), indicating that cardiotoxicity was effectively induced 
in the sample studied. Injection of MSC significantly promoted left ventricular 
function with respect to untreated Dox group.  Radial velocity aand radial 
displacement parameters were significantly decreased in Dox and Dox + C. 
sinensis groups. On the other hand, animals from Dox + MSC group showed similar 
measurements to the control group. 
5.5 Pamidronate Attenuates Oxidative Stress in Acute Doxorubicin-
Induced Cardiotoxicity 
Recent studies have shown that bisphosphonates can decrease oxidative 
stress. Therefore, the objective of this study was to evaluate the effect of pamidronate 
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on preventing acute doxorubicin-induced cardiotoxicity. The rats were allocated in 
four groups: the control group (C), the doxorubicin group (D), the pamidronate group 
(P) and the doxorubicin/pamidronate group (DP). Prior to the experiment, all animals 
were submitted to echocardiography. The rats allocated in the P and DP groups 
received a single dose of pamidronate (3 mg/kg, IP) and the C and D groups received 
sterile saline injections. Twenty-four hours after pamidronate injection, the rats 
allocated in the D and DP groups received a single dose of doxorubicin (20 mg/kg, 
IP), and the C and P groups received sterile saline injections. 
Echocardiographic indices 
Doxorubicin treatment caused a decrease in the left atrium diameter and the left 
ventricular diastolic diameter and an increase in the left ventricular posterior wall 
relative thickness (PWRT). In the DP group we observed a decrease in the PWRT 
compared with the D group. 
5.6 Daunorubicin  induced cardiotoxicity 
The cardiotoxicity was induced in a well-established schedule in male Chinchilla 
rabbits by repeated administration of daunorubicin (DAU, 3 mg/kg i.v., n = 16, 
Daunoblastina, Pfizer, Rome, Italy) once weekly for ten weeks, whereas animals in 
the control group received saline (1 mL/kg i.v., n = 16) in the same schedule. A week 
after the last administration (i.e., at the end of the treatment period), the animals in 
control and DAU group were randomized to sacrifice (n = 8 in each group) or to 
follow up for additional 10 weeks (follow up period, n = 8 in each group). In the 
follow up period LV fractional shortening lower than 20% was taken as evidence for 
severe (decompensated) heart failure.  
5.7 (alpha) tocopherol (vitamin E) induces cardiotoxicity 
The present study was undertaken to evaluate the effect of pharmacological dose of a-
tocopherol on heart from animals without previous cardiac disease. In addition, a-
tocopherol uptake in the target tissue, heart, has been determined in the current study. 
a-Tocopherol dissolved in corn oil or corn oil (Mazola 1, Sa˜o Paulo, SP, Brazil) was 
administered daily by gavage every morning for the entire 7-wk period. The a-
tocopherol supplement mixed with corn oil (250 mg a-tocopherol/[kg body wt/day]) 
was given to E group, while the C group received only corn oil. 
Echocardiographic indices 
Echocardiographic examination allowed the evaluation of cardiac remodelling using 
morphological and functional variables, which are presented in Tables 2 and 3. 
Pharmacological dose of a-tocopherol was associated with significant decrease in left 
ventricular end-diastolic diameter (LVD) and aortic diameter (Ao), left ventricle 
fractional shortening (FS), ejection fraction (EF) and transmitral flow early peak 
velocity (E). There were no echocardiographic changes in the control group. The 
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current study indicates a cardiac harmful effect of pharmacological dose of a-
tocopherol even under healthy conditions. 
5.8 Cyclophosphamide induced cardiotoxicity in WT and GSTP null mice 
Cyclophosphamide (CY; Cytoxan®) is a widely used anti-neoplastic drug for the 
treatment of lymphomas, brain cancer and leukemia, and as a preparatory treatment 
for bone marrow transplant. Because of its immunosuppressive activity, it is also 
frequently used for the treating autoimmune diseases, amyloidosis, idiopathic 
nephritis, severe rheumatoid arthritis and multiple sclerosis. Several of these treatment 
regimens require high doses of CY that are associated with significant side effects 
such as bone marrow suppression, and hemorrhagic cystitis that vary in incidence, 
manifestation and severity. However, some of the most serious side effects of high 
dose CY-containing regimens are associated with the acute cardiotoxic effects of the 
drug that usually manifest as endothelial damage followed by extravasation of toxic 
metabolites, and myocyte damage leading to diastolic contractile dysfunction. 
Frequent occurrences of acute fulminant congestive heart failure, hemorrhagic 
myopericarditis and sudden death have also been reported. Even though cardiac 
complications of CY therapy have declined due to recent adoption of 
multifractionated schedule of administration, the incidence of the cardiotoxic effects 
of CY treatment remains high. High dose CY infusion induces reversible stage 3 heart 
failure in 10% of metastatic breast cancer patients with a median decline in ejection 
fraction of 31% and nearly 40% of patients undergoing pediatric allogenic 
hematopoietic stem cell transplantation treated with high dose CY experience cardiac 
complications. In adult populations treated with CY, mortality rates up to 20% (breast 
cancer trial) have been reported Nevertheless, the mechanism of CY cardiotoxicity 
remains unclear, and there is an urgent need to better understand the acute cardiac 
effects of CY in order to treat or minimize cardiotoxicity of high dose CY 
chemotherapy.  
Echocardiographic indices 
To examine the selective effects of CY on cardiac injury, they measured cardiac 
function by echocardiography at 1h and 4h post-CY (300 mg/kg) in WT and GSTP-
null mice. CY modestly, yet significantly, altered cardiac dimensions and function in 
both WT and GSTP-null mice with most changes occurring at 1h, and then 
diminishing or resolving by 4h post-CY.  For example, CY significantly increased the 
velocity of circumferential fiber shortening (Vcf and Vcfc, i.e., the latter is corrected 
for heart rate) in GSTP-null, but not WT, hearts at 1h, an effect that was statistically 
insignificant (p=0.087) at 4h post-treatment.  In contrast, CY-induced a significant 
increase in fractional change in area (FAC; %) in both WT and GSTP-null at 1h post-
CY that was a function of decreased end systolic area (ESA, mm
2
) in both WT and 
null mice.  The effects of CY on ESA and FAC were absent in both WT and GSTP-
null hearts at 4h post-treatment indicating this effect was reversible. This observation 
is consistent with clinical literature showing that high-dose CY associated cardiac 
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toxicity is potentially reversible.  Surprisingly, ejection fraction (EF) was slightly 
increased in WT mice at both 1h and 4h post-CY yet unaffected in GSTP-null hearts 
(p=0.053; 1h only).  Increased EF was likely due to decreased end systolic volume 
(ESV) at 1h (p=0.014) and 4h (p=0.062) in WT hearts, and ESV reflects more 
complete emptying of LV in WT hearts than in GSTP-null (p=0.10) mice. Ejection 
time (ET, a measure of aortic blood flow velocity) was significantly decreased in 
GSTP-null hearts only at 4h post-CY. These data indicate that GSTP-null hearts were 
more sensitive to acute cardiac injury due to a rapid-onset and reversible form of 
altered contractility than that observed in WT mice. 
5.9 Doxorubicin induced cardiotoxicity in wild-type (WT) mice and Mrp1 
null (Mrp1
−/−
) littermates 
Doxorubicin (DOX), an effective cancer chemotherapeutic agent, induces dose-
dependent cardiotoxicity, in part due to its ability to cause oxidative stress. We 
investigated the role of multidrug resistance–associated protein 1 (Mrp1/Abcc1) in 
DOX-induced cardiotoxicity in C57BL wild-type (WT) mice and their Mrp1 null 
(Mrp1
−/−
) littermates. Male mice were administered intraperitoneal DOX (3 or 2 
mg/kg body weight) or saline twice a week for 3 weeks and examined 2 weeks after 
the last dose (protocol A total dose: 18 mg/kg) or for 5 weeks, and mice were 
examined 48 hours and 2 weeks after the last dose (protocol B total dose: 20 mg/kg). 
Chronic DOX induced body weight loss and hemotoxicity, adverse effects 
significantly exacerbated in Mrp1
−/−
 versus WT mice. In the heart, significantly 
higher basal levels of glutathione (1.41-fold ± 0.27-fold) and glutathione disulfide 
(1.35-fold ± 0.16-fold) were detected in Mrp1−/− versus WT mice, and there were 
comparable decreases in the glutathione/glutathione disulfide ratio in WT and 
Mrp1
−/−
 mice after DOX administration. 
 Echocardiographic indices 
DOX induced comparable increases in 4-hydroxynonenal glutathione conjugate 
concentration in hearts from WT and Mrp1
−/−
 mice. However, more DOX-induced 
apoptosis was detected in Mrp1
−/−
 versus WT hearts (P < 0.05) (protocol A), and 
cardiac function, assessed by measurement of fractional shortening and ejection 
fraction with echocardiography, was significantly decreased by DOX in 
Mrp1
−/−
 versus WT mice (P < 0.05; 95% confidence intervals of 20.0%–24.3% versus 
23.7%–29.5% for fractional shortening, and 41.5%–48.4% versus 47.7%–56.7% for 
ejection fraction; protocol B). Together, these data indicate that Mrp1 protects the 
mouse heart against chronic DOX-induced cardiotoxicity. 
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5.10 N-Acetyl Cysteine Amide in the Prevention of Doxorubicin and 
Trastuzumab–Mediated Cardiac Dysfunction 
N-acetyl cysteine amide (NACA), is a thiol structural analog of NAC, with increased 
lipophilicity and bioavailability, allowing it to traverse the cellular lipid bilayer. 
Previous investigations into the anti-oxidant properties of NACA have demonstrated 
that the compound is able to: i) scavenge free radicals and protect red blood cells from 
OS; ii) protect the blood brain barrier from OS in mice exposed to methamphetamine; 
and iii) reduce the levels of OS in embryonic rat cardiomyocytes exposed to DOX in 
vitro. The anti-oxidant properties of NACA from these previous studies provide a 
strong rationale to investigate whether it may provide cardioprotection against 
DOX+TRZ mediated cardiotoxicity in the in vivo setting.  
Echocardiographic indices 
In mice receiving DOX, left ventricular ejection fraction (LVEF) decreased from 
73±4% to 43±2% at day 10. In mice receiving DOX+TRZ, LVEF decreased from 
72±3% to 32±2% at day 10. Prophylactic administration of NACA to mice receiving 
DOX or DOX+TRZ was cardio-protective, with a LVEF of 62±3% and 55±3% at day 
10, respectively. Histological and biochemical analyses demonstrated loss of cellular 
integrity, increased oxidative stress (OS), and increased cardiac apoptosis in mice 
treated with DOX+TRZ which was attenuated by the prophylactic administration of 
NACA. Conclusions: NACA attenuated the cardiotoxic side effects of DOX+TRZ in 
a murine model of chemotherapy induced cardiac dysfunction by decreasing OS and 
apoptosis. 
5.11 Angiotensin Type I Receptor Antagonist, Fimasartan, Prevents 
Doxorubicin-induced Cardiotoxicity 
Angiotensin receptor blockers (ARBs) have organ-protective effects in heart failure 
and may be also effective in doxorubicin-induced cardiomyopathy (DOX-CMP); 
however, the efficacy of ARBs on the prevention of DOX-CMP have not been 
investigated. We performed a preclinical experiment to evaluate the preventive effect 
of a novel ARB, fimasartan, in DOX-CMP. All animals underwent echocardiography 
and were randomly assigned into three groups: treated daily with vehicle (DOX-only 
group, n=22), 5 mg/kg of fimasartan (Low-fima group, n=22), and 10 mg/kg of 
fimasartan (High-fima group, n=19). DOX was injected once a week for six weeks. 
Echocardiography and hemodynamic assessment was performed at the 8th week using 
a miniaturized conductance catheter. Survival rate of the High-fima group was greater 
(100%) than that of the Low-fima (75%) and DOX-only groups (50%). 
Echocardiography showed preserved left ventricular (LV) ejection fraction in the 
High-fima group, but not in the DOX-only group (P=0.002). LV dimensions 
increased in the DOX-only group; however, remodeling was attenuated in the Low-
fima and High-fima groups. Hemodynamic assessment showed higher dP/dt in the 
High-fima group compared with the DOX-only group. A novel ARB, fimasartan, may 
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prevent DOX-CMP and improve survival rate in a dose-dependent manner in a rat 
model of DOX-CMP and could be a treatment option for the prevention of DOX-
CMP. 
Echocardiographic indices 
Echocardiographic data showed progressive LV systolic dysfunction and dilation of 
the LV cavity in the DOX-only group. Specifically, LVESD at six weeks was 
maintained until end of the study in both the High-fima (4.94±1.08 mm) and Low-
fima (4.95±0.52 mm) groups; however, LVESD in the DOX-only group was 
significantly increased compared with the fimasartan-treated groups (56±0.6 
mm, P=0.009 by ANOVA). Furthermore, LVEF was preserved in the High-fima 
group (71.4%±6.3%) and slightly decreased in the Low-fima group (67.9%±5.3%) 
compared with the NC group (74.6%±3.7%). In contrast, LVEF was significantly 
decreased in the DOX-only group (54.6%±8.4%, P<0.001 by ANOVA). 
5.12 Renin angiotensin system antagonists in the prevention of 
doxorubicin and trastuzumab induced cardiotoxicity. 
The objective of the current study was to determine whether inhibition of the RAS 
pathway at three distinct levels, including direct renin inhibition (DRI; Aliskiren), 
angiotensin converting enzyme inhibition (ACEI; Perindopril), and angiotensin 
receptor blockade (ARB; Valsartan) can prevent cardiac dysfunction in a chronic in 
vivo model of DOX+TRZ mediated cardiotoxicity. 
The pathogenesis of DOX+TRZ mediated cardiotoxicity is multifactorial, there is 
accumulating evidence to suggest the RAS as a key contributor. Angiotensin II plays 
an important role as a vasoconstrictor agent and a mitogenic factor by interacting with 
the AT1R in cardiovascular myocytes. Although DOX induces myofibrillar loss, 
apoptosis, and significantly impairs contractile function in WT mice, this drug 
induced cardiotoxicity was not observed in AT1R-knockout mice or in animals treated 
with AT1R blockade. These findings suggest a contributory role for the RAS pathway 
in the development of DOX mediated cardiotoxicity. The administration of the ARB 
Telmisartan (10 mg/kg/day for 7 days), was cardioprotective in rats treated with a 
single dose of 20 mg/kg DOX, by decreasing lipid peroxidation, GSH depletion, and 
oxidative stress. Additionally, in a chronic rat model of DOX induced cardiotoxicity 
(DOX 25 mg/kg for a 6 week period), Enalapril served to preserve mitochondrial 
function, down-regulate free radical production, and preserve overall cardiac function. 
Finally, in a chronic rat model of DOX (15 mg/kg) mediated cardiac dysfunction, the 
prophylactic administration of either ACEI (Captopril 60 mg/kg) or ARB 
(Telmisartan 10 mg/kg) proved to be cardioprotective . This was evidenced by a 
significant reduction in the concentration of cardiac biomarkers and oxidative stress, 
and by the maintenance of characteristic cardiac histology in rats pre-treated with 
RAS antagonism. Our current study adds to the existing literature which supports the 
cardioprotective capabilities of RAS antagonism in a chronic murine model of 
chemotherapy induced cardiac dysfunction. Our study is the first to also demonstrate 
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the potential cardioprotective role of direct renin inhibition, specifically Aliskiren, in 
preventing DOX mediated cardiotoxicity. Additionally, although previous animal 
studies have focussed on a DOX only model, we have extended our important 
findings to a combined DOX+TRZ model, mimicking the clinical setting of breast 
cancer. 
Experimental protocol 
A total of 240 C57Bl/6 male mice were randomized to one of the following 
prophylactic treatment arms: (A) placebo (saline; n = 60); (B) Aliskiren (50 mg/kg; 
n = 60); (C) Perindopril (3 mg/kg; n = 60); or (D) Valsartan (10 mg/kg; n = 60) 
(Figure 1). RAS antagonists were administered orally by gavage on a daily basis for 
the entire study period of 13 weeks. Furthermore, mice from each prophylactic 
treatment arm were randomized to one of the following chemotherapeutic regimens: 
(i) TRZ (4 mg/kg weekly, intraperitoneal (i.p.); n = 20); (ii) DOX (4 mg/kg weekly, 
i.p.; n = 20); or (iii) DOX+TRZ (n = 20) (Figure 1). TRZ, DOX, or DOX+TRZ 
injections were initiated at week 2, following 2 weeks of prophylactic treatment with 
a RAS antagonist or placebo, and continued for 5 weeks (Figure 2). The cumulative 
doses of DOX or TRZ achieved were the minimum concentration to induce a 
chemotherapy mediated cardiomyopathy, as previously validated by our group and 
others [26-28]. Cardiac function was evaluated over the course of the study via serial 
murine echocardiography. Mice were imaged at baseline and weekly until 
euthanization at week 13. 
 
Echocardiographic indices 
Echocardiographic indices, including HR, PWT, LVID, LVFS, and LVEF were 
within normal physiologic limits for all mice at baseline. No significant change from 
baseline value was observed for HR or PWT at week 13 in any of the treatment arms. 
In C57Bl/6 mice treated with TRZ, there were no significant changes in LV cavity 
dimensions as compared to baseline. Mice treated with DOX alone demonstrated a 
significant increase in cavity dimensions, as the LVID increased from 3.2 ± 0.1 mm at 
baseline to 4.5 ± 0.2 mm at week 13 (p < 0.05). Mice receiving DOX+TRZ treatment 
demonstrated a similar increase in LVID from 3.1 ± 0.2 mm at baseline to 
4.6 ± 0.3 mm at week 13 (p < 0.05). Pre-treatment with Aliskiren, Perindopril, and 
Valsartan significantly reduced LVID in mice administered DOX alone from 
4.5 ± 0.2 mm to 3.6 ± 0.2 mm, 3.9 ± 0.2 mm, and 4.0 ± 0.2 mm, respectively, at week 
13 (p < 0.05). Similarly, in mice treated with DOX+TRZ, the prophylactic 
administration of Aliskiren, Perindopril, and Valsartan significantly reduced LVID at 
week 13 from 4.6 ± 0.3 mm to 3.9 ± 0.2 mm, 4.1 ± 0.2 mm, and 4.2 ± 0.1 mm, 
respectively, (p < 0.05). 
LVFS did not change from baseline values in mice administered TRZ over the course 
of the 13 week study. In mice treated with DOX alone, LVFS decreased from 51 ± 1% 
at baseline to 32 ± 2% at week 13 (p < 0.05). Pre-treatment with Aliskiren, 
Perindopril, and Valsartan attenuated DOX induced LV impairment, improving LVFS 
values to 45 ± 1%, 38 ± 1%, and 37 ± 2%, respectively, at week 13 (p < 0.05). In mice 
treated with the combination of DOX+TRZ, LVFS further decreased from 52 ± 2% at 
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baseline to 26 ± 2% at week 13 (p < 0.05). Prophylactic treatment with Aliskiren, 
Perindopril, and Valsartan significantly improved LVFS to 40 ± 1%, 32 ± 1%, and 
33 ± 2%, respectively, at week 13 (p < 0.05). 
 
5.13 Ginsenoside Rg3 antagonizes adriamycin-induced cardiotoxicity 
by improving endothelial dysfunction from oxidative stress via 
upregulating the Nrf2-ARE pathway through the activation of akt 
Ginseng, the root of Panax ginseng C.A. Meyer, is well known in herbal medicine as 
a tonic and restorative agent. The main ingredient responsible for the actions of 
ginseng is the ginsenoside. Ginsenoside Rg3 (Rg3), an active ingredient of Panax 
ginseng, is a commercially available ginsenoside (Shenyi Capsule) that is used to 
inhibit and prevent cancers. Rg3 has been shown to increase the efficacy of cancer 
chemotherapy with anti-carcinogenic and anti-metastatic processes. They also found 
that Rg3 could inhibit the cell viability and proliferation on human breast 
adenocarcinoma cells (MCF-7) with or without ADM (Supplementary files). Rg3 
reportedly displays antioxidative and cardioprotective effects. These findings provide 
evidence that Rg3 might have potential therapeutic effects for cardiac damage caused 
by ADM-induced oxidative stress. 
Adriamycin (doxorubicin hydrochloride, 99%, Solarbio, Beijing, China) was 
administered via a single intraperitoneal dose of 15 mg/kg in the ADM and ADM/Rg3 
group. The control group received normal saline. One hour after the injection, 
ginsenoside Rg3 (10, 20, 40 mg/kg daily, > 98%, Mansite, Chengdu, China) was 
injected intraperitoneally in the ADM/Rg3 groups. Rats in the ADM group were 
treated with saline instead. The cardiac function was evaluated with echocardiography 
at baseline before the ADM treatment and 3, 7, and 14 days after the ADM injection. 
Rats were anesthetized using 3% inhalant isoflurane in 100% oxygen and maintained 
in 1.5–2% isoflurane during the echocardiogram testing. M-mode, B-mode and left 
ventricular outflow tract (LVOT) ultrasound images were obtained by a Vevo 2100 
ultrasound system (Visualsonics, Toronto, Canada) using 8 rats for each observation 
(total of 40 rats). 
Echocardiography indices 
They examined the effect of the combination treatment with Rg3 using an in vivo rat 
model of ADM-induced cardiotoxicity. The rats were treated with ADM or a 
combination of ADM and Rg3 (10, 20, and 40 mg/kg) for 14 days and examined by 
M-mode and LVOT echocardiography. The ejection fraction (EF) and fractional 
shortening (FS) were significantly decreased in the rats given ADM treatment alone. 
Co-treatment with Rg3 significantly increased the EF and FS to maximums of 85.45% 
and 56.04% (P = 0.000 and 0.011 by 40 mg/kg Rg3 at the 14th day. ADM induced a 
significant increase in the left ventricle (LV) mass, and 40 mg/kg Rg3 could 
dramatically inhibit the LV mass increase (P = 0.038). On Fig. 2. Testing the 
endothelium function by an aortic ring assay. ADM or ADM/Rg3 (20 mg/kg) treated 
Institutional Repository - Library & Information Centre - University of Thessaly
07/06/2020 18:19:02 EEST - 137.108.70.13
- 33 - 
 
S.D. rats were killed on the 14th day after the ADM-injection, and the thoracic aortas 
were rapidly dissected out for the following assay. The aorta rings were pre-treated 
with 1 μM NE to achieve a plateau phase, and then 10 μM Ach was added to induce 
vasodilation. Parallel experiments were performed on control rats with intact 
endothelium or mechanically denuded endothelium. (A) Vascular tone after NE and 
Ach treatment. The maximal constriction appeared at 6 min after the NE incubation, 
and then Ach was added to achieve vasodilation. (B) Maximal constriction and 
dilation by NE and Ach. The ADM and endothelium-denuded aortas showed 
increased contraction and decreased dilatation than the intact endothelium aortas. 
Cotreatment with Rg3 could partially recover the abnormal function of vasodilation 
and vasoconstriction. ∗P < 0.05 versus endothelium-intact, ∗∗P < 0.01 versus 
endotheliumintact; #P < 0.05 versus ADM-treated. The values are the mean ± S.D., n 
= 8. LVOT echocardiography, the peak aortic blood velocity (Vel) was significantly 
lower in the ADM-treat group (P = 0.047) but not in the co-treatment groups. 
Thoracic aortas were rapidly dissected out of ADM or ADM/Rg3 (20 mg/kg) treated 
rats on the 14th day after the ADM-injection. The aorta rings were pre-treated with 1 
μM NE to achieve a plateau phase. In the control group, the vascular tone of the 
endotheliumintact aorta rings reached 3.27 ± 0.32 g from the baseline value of 2 g; the 
vascular tone of the endothelium-denuded aortas was 3.93 ± 0.27 g. Next, 10 μM Ach 
was added to induce vasodilation. The relaxation was more than 80% compared with 
the plateau phase in the endothelium-intact aortas and less than 30% in the 
endotheliumdenuded aortas. In the ADM treated rats, the maximal constriction by NE 
was close to level of constriction of the endothelium-denuded aortas, which was up to 
4.07 ± 0.40 g. With the Ach administration, the vascular tone was reduced to 3.37 ± 
0.21 g, and the maximal vasodilatation was 34%, showing significant endothelium 
dysfunction. Compared with the ADM group, the group co-treated with Rg3 showed 
less NE-induced constriction and more Ach-induced relaxation 
  
5.14 Fetal Rat Hearts Do Not Display Acute Cardiotoxicity in Response to 
Maternal Doxorubicin Treatment 
They analyzed the acute effect of doxorubicin, an anthracycline derivative, on fetal 
and maternal rat myocardium. They injected 10 or 20 mg/kg i.v. doxorubicin to 
pregnant Wistar rats at day 18 of pregnancy; age-matched pregnant rats injected with 
physiologic saline served as controls. Maternal echocardiography and fetal Doppler 
scanning were performed before the injection and before sacrifice. Cesarean operation 
was performed at day 19 or 20, and maternal and fetal blood samples and heart 
biopsies were collected to measure apoptosis, the impact on cell proliferation, and 
structural cardiac damage. Acute maternal cardiotoxicity is associated with loss of 
body weight, moderately deteriorated left ventricular function, induction of apoptosis, 
and a decrease in cell turnover. Despite a 30% lower fetal body weight and elevated 
plasma B-type natriuretic peptide concentrations after doxorubicin administration, the 
fetal hearts had intact microstructure, an unaltered number of apoptotic cells, and 
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preserved cell proliferation compared with controls. Our study suggests that acute 
treatment using anthracyclines during pregnancy impairs maternal cardiac function, 
whereas fetal hearts are protected. 
After 1 week of acclimatization, 80-day-old female rats were mated in separate cages 
overnight. Day 0.5 (E0.5) of pregnancy was established when spermatozoa were 
found in vaginal smears. Doxorubicin was administered after E17 to avoid 
embryotoxicity, and the highest doses were used to induce an eventual cardiotoxicity 
(E9–12). At E18.5, rats were randomized into six groups (n = 6 to 7 for each group) 
as follows: doxorubicin-treated (10 mg) and killed after 24 (group I) and 48 hours 
(group II); doxorubicin-treated (20 mg) and killed after 24 (group III) and 48 hours 
(group IV); and saline-treated controls killed after 24 (group V) and 48 hours (group 
VI). Finally, the effect of higher doxorubicin dose on cellular proliferation was tested 
in additional rats (saline or doxorubicin 20 mg for 48 hours, n = 3, for each) using 5-
bromo-2-deoxyuridine (BrdU; Sigma-Aldrich, St. Louis, MO) incorporation 
Echocardiographic indices  
A decrease in heart rhythm is a phenomenon that occurs after doxorubicin 
administration. The greatest decrease (30 heartbeats per minute) in heart rhythm was 
observed with 10 mg of doxorubicin after 48 hours. Dimensions of the maternal heart, 
measured using echocardiography, were comparable between the different groups 
subjected to saline or doxorubicin administration, although there was a trend for 
reduced end-diastolic dimensions after 20 mg of doxorubicin, possibly related to 
impaired fluid intake. After administration of 20 mg of doxorubicin for 48 hours, the 
left posterior wall thickness in diastole was significantly decreased (P < 0.05), 
whereas the left ventricular internal diameter and interventricular septum in diastole 
did not change significantly (P = 0.16 and 0.18). Systolic thickening of the septum 
was markedly reduced. Global myocardial function, measured as FS, was 
significantly decreased by 5–10% 24 and 48 hours after 20-mg bolus injection of 
doxorubicin. The umbilical systolic peak velocity and the ductus venosus Doppler 
measurements did not show significant differences between the groups.  
 
5.15 Cardiotoxicity of the anticancer therapeutic agent bortezomib 
Recent case reports provided alarming signals that treatment with bortezomib might 
be associated with cardiac events. In all reported cases, patients experiencing cardiac 
problems were previously or concomitantly treated with other chemotherapeutics 
including cardiotoxic anthracyclines. Therefore, it is difficult to distinguish which 
components of the therapeutic regimens contribute to cardiotoxicity. Here, we 
addressed the influence of bortezomib on cardiac function in rats that were not treated 
with other drugs. Rats were treated with bortezomib at a dose of 0.2 mg/kg thrice 
weekly. Echocardiography, histopathology, and electron microscopy were used to 
evaluate cardiac function and structural changes. Respiration of the rat heart 
Institutional Repository - Library & Information Centre - University of Thessaly
07/06/2020 18:19:02 EEST - 137.108.70.13
- 35 - 
 
mitochondria was measured polarographically. bortezomib treatment leads to left 
ventricular contractile dysfunction manifested by a significant drop in left ventricle 
ejection fraction. Dramatic ultrastructural abnormalities of cardiomyocytes, especially 
within mitochondria, were accompanied by decreased ATP synthesis and decreased 
cardiomyocyte contractility. Monitoring of cardiac function in bortezomib-treated 
patients should be implemented to evaluate how frequently cardiotoxicity develops 
especially in patients with pre-existing cardiac conditions, as well as when using 
additional cardiotoxic drugs. 
Male Wistar rats (250 to 350 g) were used in the experiments.  Rats were injected i.p. 
with 0.2 mg/kg of bortezomib three times a week for 1 to 3 weeks. Wash-out indicates 
time after treatment termination. 
Echocardiographic indices 
Echocardiographic analysis revealed left ventricular contractile dysfunction 
manifested by a significant drop in left ventricle ejection fraction which was detected 
already after second dose of bortezomib. This effect was accompanied by proportional 
decrease in LV fractional shortening and a rise in LV systolic area. There were no 
changes in LV diastolic area, heart rate, or blood pressure in bortezomib-treated rats. 
 
5.16 Atorvastatin Ameliorates Radiation-Induced Cardiac Fibrosis in 
Rats 
Radiation-induced heart injury is one of the major side effects of radiotherapy for 
thoracic malignancies. Previous studies have shown that radiotherapy induced 
myocardial fibrosis and intensified myocardial remodeling. In this study, we 
investigated whether atorvastatin could inhibit radiation-induced heart fibrosis in 
Sprague-Dawley rats, which were randomly divided into six groups: control; radiation 
only; and four treatment groups receiving atorvastatin plus radiation (E1, E2, E3 and 
E4). All rats, except the control group, received local heart irradiation in 7 daily 
fractions of 3 Gy for a total of 21 Gy. Rats in groups E1 (10 mg/kg/day) and E2 (20 
mg/kg/day) received atorvastatin and radiation treatment until week 12 after exposure. 
Rats in groups E3 (10 mg/kg/day) and E4 (20 mg/kg/day) received atorvastatin 
treatment from 3 months before irradiation to week 12 after irradiation. The 
expressions of TGF-β1, Smad2, Smad3, fibronectin, ROCK I and p-Akt in heart 
tissues were evaluated using real-time PCR or Western blot analyses. Atorvastatin 
significantly reduced the expression of TGF-β1, Smad3/P-Smad3, ROCK I and p-Akt 
in rats of the E1-E4 groups and in a dose-dependent manner. Fibronectin exhibited a 
similar pattern of expression changes. In addition, echocardiography showed that 
atorvastatin treatment can inhibit the increase of left ventricular end-diastolic 
dimension, left ventricular end-systolic diameter and left ventricular posterior wall 
thickness, and prevent the decrease of ejection fraction and fraction shortening in E1-
E4 groups compared with the radiation only group. This study demonstrated that 
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radiation exposure increased the expression of fibronectin in cardiac fibroblasts and 
induced cardiac fibrosis through activation of the TGF-β1/Smad3, RhoA/ROCK, and 
PI3K/AKT signaling pathways. Statins ameliorated radiation-induced cardiac fibrosis 
in Sprague-Dawley rats. Our results suggest that atorvastatin is effective for the 
treatment of radiation-induced cardiac fibrosis, especially with longer and higher dose 
atorvastatin treatment, as demonstrated in experimental group E4. 
Echocardiographic indices  
Echocardiography was used to measure functional parameters (LVEDD, LVESD, 
LVPWT, EF and FS) to validate the effect of fibrosis reduction by statins. In the 
radiation only and E1–E3 groups, all of the parameters showed significant differences 
compared to pre-atorvastatin treatment. Comparison with the control group showed 
similar results. Significant differences were detected among the E1–E4 and radiation 
only groups, indicating that atorvastatin treatment can inhibit the increase of LVEDD, 
LVESD and LVPWT, and prevent the decrease of EF and FS. These effects were in a 
dose-dependent manner, which means the E4 group exhibited significantly improved 
cardiac-fibrotic status compared to the other groups 
 
5.17 NC-6300, an epirubicin-incorporating micelle, extends the 
antitumor effect and reduces the cardiotoxicity of epirubicin 
Epirubicin is widely used to treat various human tumors. However, it is difficult to 
achieve a sufficient antitumor effect because of dosage limitation to prevent 
cardiotoxicity. We hypothesized that epirubicin-incorporating micelle would reduce 
cardiotoxicity and improve the antitumor effect. NC-6300 comprises epirubicin 
covalently bound to PEG polyaspartate block copolymer through an acid–labile 
hydrazone bond. The conjugate forms a micellar structure of 40–80 nm in diameter in 
an aqueous milieu. NC-6300 (10, 15 mg/kg) and epirubicin (10 mg/kg) were given 
i.v. three times to mice bearing s.c. or liver xenograft of human hepatocellular 
carcinoma Hep3B cells. Cardiotoxicity was evaluated by echocardiography in 
C57BL/6 mice that were given NC-6300 (10 mg/kg) or epirubicin (10 mg/kg) in nine 
doses over 12 weeks. NC-6300 showed a significantly potent antitumor effect against 
Hep3B s.c. tumors compared with epirubicin. Moreover, NC-6300 also produced a 
significantly longer survival rate than epirubicin against the liver orthotopic tumor of 
Hep3B. With respect to cardiotoxicity, epirubicin-treated mice showed significant 
deteriorations in fractional shortening and ejection fraction. In contrast, cardiac 
functions of NC-6300 treated mice were no less well maintained than in control mice. 
This study warrants a clinical evaluation of NC-6300 in patients with hepatocellular 
carcinoma or other cancers. 
Echocardiographic indices 
Left ventricular dimensions and wall thicknesses were determined from the 
echocardiography images, and ejection fraction (EF) and fractional shortening (FS) 
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were automatically calculated. (a) Changes in EF; ANOVA test between NC-6300 
(10 mg/kg) and EPI (10 mg/kg), P = 0.0081. (b) Changes in FS; ANOVA test between 
NC-6300 (10 mg/kg) and EPI (10 mg/kg), P = 0.0114. Arrows, drug injections; bars, 
SD; points, mean. 
  
 
 
5.18 Use of M-mode and Doppler echocardiography to investigate 
the cardiotoxicity of minoxidil in beagle dogs. 
Doppler and M-mode echocardiography (EC) were used to investigate the effects of 
minoxidil on the cardiac function of the dog and potentially to clarify the 
pathogenesis of cardiac lesions, in particular the necrotic lesion in the left ventricle 
and the haemorrhagic lesion in the right atrium. Groups of three dogs were treated 
with a single oral dose of 0.5 or 2 mg/kg minoxidil or control vehicle, and M-mode 
and Doppler parameters were recorded at different time points before as well as 1, 3 
and 24 h after treatment. The treatment produced a number of changes in M-mode 
parameters that indicate an increase in left ventricle contractility, in particular, 
increases in the percentage of thickening of the left ventricle wall during systole and 
in ejection fraction, and decrease of systolic volume. There was also a decrease in 
diastolic volume, which indicates a decrease in filling of the left ventricle probably 
due to the tachycardia and subsequent decrease in inter-systolic time. Doppler EC 
showed an increase in the velocity of the aortic flow, which indicates an increase in 
cardiac contractility. There was also a mild increase in stroke volume, which together 
with the tachycardia resulted in a marked increase in cardiac output. Together, 
Doppler and M-mode recordings gave evidence of an increase in the contractility of 
the left ventricle. This change is consistent with the generally accepted mechanism for 
the development of the left ventricle lesion induced by minoxidil. Minoxidil also 
produced changes in atrio-ventricular flows. The velocity and/or acceleration of E- 
and A-waves of the mitral and tricuspid flows increased, and the E/A ratio decreased. 
The changes in the E-wave indicate a faster diastole of the ventricle probably to 
compensate for the decrease in inter-systolic time. The changes in A wave are 
characteristic of an increased amplitude and velocity of the atrial contraction. This 
latter change is much more marked for tricuspid than for mitral flow. For both flows 
the E/A ratio decreased, which indicates that the contraction of the atria plays an 
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increased role in ventricle filling after minoxidil treatment. This stimulation of atrial 
contraction that we evaluate with Doppler EC may play a key role in the development 
of the atrial lesion produced by minoxidil. The fact that the change is more marked in 
the right than in the left atrium may explain why the lesion occurs only in the right 
atrium in dogs. This study showed, therefore, that Doppler EC associated with M-
mode EC is a useful method for obtaining pertinent information on the pathogenesis 
of the left ventricle lesion induced by haemodynamic mechanisms. Moreover, 
Doppler EC allowed the assessment of changes in the function of the right atrium that 
may be involved in the development of the right atrial lesion. 
Echocardiographic indices 
Changes in echocardiographic parameters were seen in the left ventricle and in the 
atria, and they can be associated with two different cardiac lesions produced by 
minoxidil. In addition to the marked tachycardia, both dose levels given in the current 
study produced changes in echocardiographic parameters consistent with stimulatory 
effects on the left ventricle. The increase in percentage thickening of the septum and 
of the posterior wall of the ventricle indicated an increase in the force of contraction 
of the left ventricle myocardium. The decrease in end systolic volume and the 
increase in ejection fraction showed an increase in the amplitude and efficiency of the 
left ventricle beat. These changes in the contractile function of the left ventricle seen 
in M-mode EC are associated with effects on the aortic flow that were assessed by 
Doppler measurements. In particular, the increase in maximal velocity, acceleration 
and time–velocity integral of the aortic wave are consequences of the increase in the 
amplitude and force of the left ventricle beat. In addition, changes in 
echocardiographic parameters reflected the increase in heart rate. The decrease in end 
diastolic volume is mainly due to the marked tachycardia and consequent decrease in 
diastolic time, which reduces ventricle filling. The decrease in ejection time is the 
Doppler correlate of a decrease in systolic time. The marked increase in the rate of 
circumferential fibre shortening reflected the increase both in the amplitude and in the 
velocity of the cardiac contraction. The end result of these changes in left ventricle 
function was a mild increase in the stroke volume determined by Doppler EC that, 
together with the increase in heart rate, produced a marked increase in cardiac output. 
 
5.19 High-dose testosterone and dehydroepiandrosterone 
induce cardiotoxicity in rats: Assessment of echocardiographic, 
morphologic, and oxidative stress parameters 
The aim of this study is to assess cardiotoxic effect of testosterone (TES) and 
dehydroepiandrosterone (DHEA) in Sprague Dawley rats. We compared the impact of 
subacute (14 days) and subchronic (90 days) administration of suprapharmacologic 
doses of TES and DHEA on body weight, locomotor activity, muscle strength, 
echocardiographic parameters, heart histopathology, and oxidative stress markers with 
the control group. Testosterone (10, 30, and 100 mg/100 g body weight) and DHEA 
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(10 mg/100 g body weight) administration decreased the body weights and locomotor 
activity (p < 0.05), and the combination of both increased muscle strength (p < 0.05) 
in rats. In our histopathological evaluation, misshapen cell nuclei, disorganized 
myocardial fibers, and leukocytic infiltrates were observed in high-dose TES (100 
mg/100 g)-treated rats, especially on day 14. On day 90, mild changes such as 
misshapen cell nuclei, disorganized myocardial fibers, and leukocytic infiltrates were 
observed in TES and DHEA-treated groups. According to our echocardiographic 
study on day 14 and day 90, TES, especially at high doses, induced increase in left 
ventricular posterior wall diameter and ejection fraction (p < 0.05). In this study, 
blood oxidative stress marker malondialdehyde was increased slightly but not 
significantly in TES and DHEA groups. On the other hand, antioxidant enzymes such 
as SOD and glutathione peroxidase (GSH-Px) levels were slightly but not 
significantly increased in TES and DHEA groups. These data demonstrate that the 
potential risk to cardiac health due to exogenous androgen use may be related to 
oxidative stress in rats. 
Echocardiographic indices 
On day 90, high doses of TES (30 mg/100 g and 100 mg/100 g) increased LWPWD 
significantly when compared with the control group (p < 0.05). Additionally, TES (30 
mg/100 g and 100 mg/100 g) increased EF and FS slightly but not significantly. TES 
(10 mg/ 100 g) increased FS significantly when compared with the control group (p < 
0.01). On the other hand, DHEA increased LWPWD, EF, and FS slightly but not 
significantly.  
 
5.20 Cardioprotective effects of rosuvastatin and carvedilol on 
delayed cardiotoxicity of doxorubicin in rats. 
The 3-hydroxy-3-methlyglutaryl coenzyme A reductase inhibitor (HMG CoA 
reductase inhibitor, statin) and carvedilol are the agents that were proved to have both 
of antioxidant properties and clinical benefits for heart failure. Of these, long-term 
cardioprotective effect of statin against delayed cardiotoxicity of doxorubicin was not 
clearly elucidated, while short-term cardioprotective effects of statin against acute 
doxorubicin cardiotoxicity were reported in a few animal studies. On the other hand, 
carvedilol is frequently used as a reference agent in the evaluation of antioxidant 
properties. Besides, a few animal studies reported antioxidant properties of carvedilol 
lead to the reduction of acute cardiotoxicity and nephrotoxicity from doxorubicin. In 
this study, low and high dose of rosuvastatin and carvedilol was co-administered with 
doxorubicin and long-term cardioprotective effect against delayed doxorubicin 
cardiotoxicity was evaluated. In addition, antioxidant effects of rosuvastatin and 
carvedilol were evaluated. 
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Echocardiographic indices 
At baseline, there was no significant difference in the LVEDD, LVESD and FS 
among the six groups. At eighth week, FS significantly decreased in all of the 
doxorubicin-treated groups (groups II–VI) compared with baseline. There was no 
significant difference in LVEDD among the groups I–VI at eighth week. All of the 
groups that were treated with doxorubicin showed an increase in LVESD and 
decrease in FS compared with group I. Although group VI showed marginally larger 
LVEDD (p = 0.061) and lower FS (p = 0.072) than group IV, there was no significant 
difference in LVESD and FS among the doxorubicin-treated groups (groups II–VI). 
 
5.21 Oleuropein prevents doxorubicin-induced cardiomyopathy 
interfering with signaling molecules and cardiomyocyte metabolism 
Anthracycline-associated cardiotoxicity has been the subject of considerable 
controversy. A variety of pathways and mechanisms have been proposed including 
impaired expression of cardiomyocyte proteins, disruption of cellular and 
mitochondrial Ca2+ homeostasis, disruption of mitochondrial bioenergetics, and 
interference with various pro-survival kinases leading to apoptosis. The most widely 
accepted mechanisms are the iron-mediated formation of reactive oxygen species 
(ROS), which promote myocardial oxidative stress. However, the ROS hypothesis has 
been tempered by a series of negative studies, while an alternative hypothesis is still 
pending. The natural phenolic compound oleuropein, which is present in high 
concentration in olives and olive tree leaves, has been shown to exert potential 
cardioprotective actions, and is capable of preventing acute DXR-induced 
cardiotoxicity. However, numerous antioxidants have been utilized for 
cardioprotection and, although efficient in cellular or acute animal experiments, they 
have failed to alleviate DXR cardiotoxicity in clinically relevant animal models or 
clinical trials. The evaluation of the potential cardioprotective effects of an 
antioxidant against DXR-induced cardiomyopathy with a parallel investigation of 
several possibly implicated pathways and use of holistic — omics techniques, is 
generally missing. As DXR is a commonly used drug in the treatment of a wide range 
of cancers, such a study would potentially provide important pathogenetic and 
therapeutic insights. The challenge for the future is to design protocols that are 
cardioprotective for both the short-term and long-term effects of doxorubicin, 
preferably without long-term administration and without hindering the antitumor 
activity of the drug. 
Echocardiographic indices 
At the end of the interventions, there were no differences among groups in LV end-
diastolic diameter. LV end-systolic diameter was marginally larger in the DXR group 
compared to controls (p = 0.052 in post-hoc analysis). However, animals in the DXR 
group had significantly lower fractional shortening compared to controls (p b 0.05) 
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and lower LV wall thickness (p b 0.05). All other groups did not differ from the 
control animals (p N 0.05). 
 
 
5.22 Effect of telmisartan in limiting the cardiotoxic effect of 
daunorubicin in rats 
The renin-angiotensin system (RAS) is a central component of the physiological and 
pathological responses of the cardiovascular system. The activity of angiotensin II 
(Ang II), the main effector of RAS, is initiated by its interaction with at least two 
pharmacologically distinct subtypes of cell-surface receptor, AT-1 and AT-2. The 
major functions of Ang II in the cardiovascular system are mediated by the AT-1 
receptor (AT1R). Recent findings have suggested that Ang II activates intracellular 
signalling processes, which leads to events that include the generation of reactive 
oxygen species (ROS), myocardial apoptosis and fibrosisRecently, some investigators 
have shown that telmisartan, an ARB, is a partial agonist of the peroxisome 
proliferative activated receptor-gamma (PPAR-g), and it is reported to possess anti-
inflammatory and antioxidant properties. To the best of our knowledge, no published 
study has investigated the cardioprotective effects of telmisartan in DNR-induced 
toxicity. In the present study, we have therefore investigated the mechanism of its 
protective effect against DNR-induced cardiotoxicity in rats, using changes in 
myocardial function, histopathology, myocardial apoptosis, and biochemical and 
oxidative-stress-related factors. 
Echocardiographic indices 
LVEDP was significantly higher and dP/dt was significantly lower in the DNR group 
than in group N, indicating LV dysfunction in the vehicle-treated DNR rats. Co-
treatment with telmisartan reduced LVEDP (11 1.2 mmHg versus 7.8 0.4 mmHg, P < 
0.05) and improved dP/dt (4722 295 mmHg/s versus 6635 90 mmHg/s, P < 0.05; and 
4327 379 mmHg/s versus 6969 141 mmHg/s, P < 0.05) significantly in comparison 
with those in group DNR. Echocardiographic data revealed that both LVDd and 
LVDs were significantly increased in group DNR compared with those in group N. In 
addition, LV systolic function, as assessed by FS and EF, was also significantly 
reduced in group DNR compared with group N. The increases in both LVDd and 
LVDs were significantly attenuated in group Telm, since FS and EF were 
significantly increased. 
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5.23 Increased efficacy and reduced cardiotoxicity of metronomic 
treatment with cyclophosphamide in rat breast cancer 
 
Cardiac toxicity, including acute lethal myocarditis resulting from high-dose CPA 
chemoradiotherapy, has been described in numerous reports. For CPA-containing 
regimens with doses ≥150 mg/kg, left ventricle dysfunction has been reported in 7% 
to 28% of patients (7). CPA-induced cardiomyopathy occurs within the initial two to 
three weeks after treatment. CPA is an inactive prodrug that undergoes a complex 
metabolic process. It is hydroxylated by the hepatic microsomal cytochrome P450 
system to its active metabolite, 4-hydroxycyclophosphamide, and its tautomer, 
aldophosphamide. These intermediates undergo either conversion into acrolein and 
phosphoramide mustard, which are believed to be the toxic and active metabolites, 
respectively, or oxidation to the inactive compound carboxyphosphamide. CPA 
metabolites can react with carboxyl, mercapto, amino, phosphate and hydroxyl groups 
and can form cross-links with DNA and proteins. 
Studies evaluating the cumulative probability of DOX-induced heart failure have 
found rates in the range of 3-5% at doses of 400 mg/m
2
 and 7 to 26% at 550 mg/m
2
. 
DOX-induced cardiomyopathy is reported to develop between 0 and 231 days 
following the final dose of DOX. However, delayed development of cardiotoxicity of 
up to 20 years following therapy has been reported, suggesting that cardiac myocytes 
are damaged during therapy. A number of different mechanisms for DOX action have 
been proposed, including free radical formation with glutathione depletion and DNA 
cross-linking. 
The aim of this study was to examine the cardiotoxicity and efficacy of metronomic 
CPA and DOX treatment on experimental breast cancer of rats. 
 Echocardiographic indices  
Echocardiographic assessment of cardiac physiological alterations. Heart rate was 
similar among the groups and was not affected significantly by tumor presence or by 
CPA and DOX treatment (range, 260-325 beats per minute). 
At two weeks after completion of the treatment, the average LVPW end-diastolic 
thickness was decreased in both DOX- and CPA-treated rats in comparison to the 
baseline, although the reduction was significant only for DOX-treated rats. LV Vol 
was increased in both CPA- and DOX-treated groups of rats in comparison to the 
baseline, but the increase was statistically significant only for the DOX-treated group. 
The average reduction of LVEF in the DOX-treated group was more than 10% 
(average 12% decrease), in comparison to the baseline and the same effect was 
detected for LVFS. The metronomic CPA also reduced LVEF but the reduction was 
only 2%. 
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5.24 The cardioprotective role of probucol against anthracycline and 
trastuzumab-mediated cardiotoxicity 
Trastuzumab (Trz), a monoclonal antibody against HER2, is effective at reducing 
both progression and recurrence of breast cancer. Despite the therapeutic benefits of 
Trz, the incidence of cardiotoxicity is increased, particularly when administered after 
anthracyclinebased chemotherapy. Clinical trials in the adjuvant setting of breast 
cancer suggest that 5% to 10% of patients develop asymptomatic cardiac dysfunction, 
requiring discontinuation of Trz. Outside of clinical trials, recent studies suggest that 
up to 1 in 4 women undergoing treatment with doxorubicin (Dox) and adjuvant Trz 
may develop cardiotoxicity. Trz may directly block anti-apoptotic signaling, leading 
to premature cardiac dysfunction. In an in vivo model of acute chemotherapy-induced 
cardiac dysfunction, Dox+Trz synergistically increased the degree of myocardial 
apoptosis. In vitro blockade of HER2 is associated with increased oxidative stress, 
which is attenuated by the administration of the antioxidant N-acetylcysteine. In 
addition, the antioxidant drug probucol (Prob) is cardioprotective against Dox-
induced cardiotoxicity by reducing apoptosis. Little is known, however, about the role 
of antioxidant therapy in the prevention of cardiotoxicity due to Dox+Trz. The aim of 
the current study was to determine whether prophylactic treatment with the 
antioxidant Prob is cardioprotective in an acute murine model of Dox and Trz-
mediated cardiomyopathy 
Echocardiographic indices 
At baseline, the LV dimensions and systolic function, as determined by both 
conventional parameters (FS and EF) and TDI indices (Vendo and SR), were similar 
in all mice. Heart rates were within normal limits at baseline. There was no evidence 
of left ventricular (LV) hypertrophy comparing posterior end-diastolic wall thickness 
at baseline and day 10 of follow-up. The LVEDD was within normal limits in all 
groups at baseline. In mice receiving Dox alone, the LVEDD increased significantly 
from 3.2 6 0.1 mm at baseline to 3.8 6 0.2 mm by day 10 (P < .05). In mice receiving 
Dox+Trz, the LVEDD increased significantly from 3.1 6 0.1 mm at baseline to 4.1 6 
0.2 mm by day 10 (P < .05). The administration of Prob, however, attenuated the 
increase in LVEDD to only 3.5 6 0.1 mm at day 10 in the Prob+Dox group and 3.6 6 
0.1 mm at day 10 in the Prob+Dox+Trz group, respectively. LV FS was within 
normal limits in all groups at baseline. In mice receiving Dox alone, the FS decreased 
from 51% 6 2% at baseline to 42% 6 2% at day 10 (P<.05). 
 
5.25 Anti-Fas gene therapy prevents doxorubicin-induced 
acute cardiotoxicity through mechanisms independent of apoptosis 
Activation of Fas signaling is a key mediator of doxorubicin cardiotoxicity, which 
involves both cardiomyocyte apoptosis and myocardial inflammation. In this study, 
acute cardiotoxicity was induced in mice by doxorubicin, and some mice 
Institutional Repository - Library & Information Centre - University of Thessaly
07/06/2020 18:19:02 EEST - 137.108.70.13
- 44 - 
 
simultaneously received an intramuscular injection of adenoviral vector encoding 
mouse soluble Fas (sFas) gene (Ad.CAG-sFas), an inhibitor of Fas/Fas ligand 
interaction. Two weeks later, left ventricular dilatation and dysfunction were apparent 
in the LacZ-treated control group, but both were significantly mitigated in the sFas-
treated group. The in situ nick-end labeling-positive rate were similar in the two 
groups, and although electron microscopy revealed cardiomyocyte degeneration, no 
apoptotic structural features and no activation of caspases were detected, suggesting 
an insignificant role of apoptosis in this model. Instead, sFas treatment reversed 
doxorubicin-induced down-regulation of GATA-4 and attenuated ubiquitination of 
myosin heavy chain and troponin I to preserve these sarcomeric proteins. In addition, 
doxorubicin-induced significant leukocyte infiltration, fibrosis, and oxidative damage 
to the myocardium, all of which were largely reversed by sFas treatment. sFas 
treatment also suppressed doxorubicin-induced p53 overexpression, phosphorylation 
of c-Jun N-terminal kinase, c-Jun, and inhibitor of nuclear factor-κB, as well as 
production of cyclooxygenase-2 and monocyte chemoattractant protein-1, and it 
restored extracellular signal-regulated kinase activation. Therefore, sFas gene therapy 
prevents the progression of doxorubicin-induced acute cardiotoxicity, with 
accompanying attenuation of the cardiomyocyte degeneration, inflammation, fibrosis, 
and oxidative damage caused by Fas signaling. 
Echocardiographic indices 
Echocardiography and cardiac catheterization performed at that time showed that 
mice receiving doxorubicin and LacZ gene had substantial deterioration of cardiac 
function characterized by enlargement of the LV cavity, increased LV diameter, 
reduced LV fractional shortening and reduced ±dP/dt, as compared with sham 
animals. Treatment with sFas gene significantly attenuated the doxorubicin-induced 
impairment of cardiac function but showed no influence on cardiac geometry and 
function in the sham-treated mice. 
 
5.26 Crocin treatment prevents doxorubicin-induced cardiotoxicity in 
rats 
CRO is well known as a unique water soluble carotenoids which is found in the 
stigmas of Crocus sativus Linne and in the fruits of Gardenia jasminoides Ellis. This 
natural compound has attracted research attention for its extensive pharmacological 
actions such as anti-inflammatory, antitumor, anti-hyperlipidemic, free radical 
scavenging, antioxidant and anti-atherosclerotic effects as well as protective against 
DNA damage. Several studies have also demonstrated that CRO has various 
neuroprotective activities in different animal models of brain disorders including 
cerebral ischemia, anxiety, depression, memory impairment, and Alzheimer's disease. 
This evidence has demonstrated the therapeutic potentials of CRO in the amelioration 
of different diseases; however, the efficacy of CRO for reducing DOX-induced 
cardiotoxicity has not yet been evaluated. Given that, the high antioxidant capacity of 
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CRO in vivo and in vitro has been shown to be the most interesting subject for 
research in recent years, in this study, we determined whether CRO could have 
cardioprotective effects in an animal model. 
Echocardiographic indices 
To assess the effect of the CRO and DOX on LV remodeling and function, a series of 
echocardiography studies were performed. As illustrated data analyses indicated that 
DOX treatment significantly decreased the FS (p b 0.01) and EF (p b 0.01), as 
compared with the Ctrl group. Moreover, the results showed that CRO 20 mg/kg and 
CRO 40 mg/kg treatments at both doses significantly increased the FS (p b 0.05 and p 
b 0.01) and EF (p b 0.05 and p b 0.01) in comparison with the DOX group. 
 
5.27 Cardioprotective effect of metformin against 
doxorubicin cardiotoxicity in rats 
Metformin is an oral antihyperglycemic drug that is used in type 2 diabetic patients. It 
has been reported to be cardioprotective in addition to decreasing basal and 
postprandial glucose levels, helping weight loss, and decreasing plasma lipid levels. 
Experimental animal models of isolated myocardial infarction and heart failure have 
shown that metformin increases the tolerance of the myocardium to ischemia-
reperfusion injury, and decreases the development of heart failure after infarction. The 
aim of the present work was to investigate whether the metformin is able to reduce the 
cardiotoxic doxorubicin effects. 
Echocardiographic indices 
Regarding left ventricular functions, the decrease in IVSTs, EF, and FS values and the 
increase in LVESD were significant in the doxorubicin group compared with that in 
the control group (p<0.05). The cardioprotective effect of metformin against left 
ventricular systolic dysfunction was observed in the doxorubicin + metformin group. 
 
5.28 Anandamide preserves cardiac function and geometry in an acute 
doxorubicin cardiotoxicity rat model 
The endogenous cannabinoid system has been reported to be protective in the 
ischemic heart as there is evidence of nitric oxide preconditioning upregulating 
endocannabinoids. It is well known that during reperfusion of the ischemic heart ROS 
are generated, ultimately resulting in depressed cardiac function. Because of the 
similarity between reperfusion injury–induced and DOX-induced cardiac dysfunction 
(ie, ROS generation), we used the N-arachidonoyl-ethanolamide (anandamide, 
ANAN) compound as a pretreatment in DOX-treated rats to investigate its use as a 
cardioprotective agent. Anandamide has been shown to interact with the endogenous 
cannabinoid system via cannabinoid receptor 1 (CB1)27 and possibly cannabinoid 
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receptor 2 (CB2), and as such, we hypothesized that treatment with ANAN would 
have a cardioprotective effect on DOX-induced acute cardiotoxicity. 
Echocardiographic indices 
This study shows promise in battling DOX cardiotoxicity due to the fact that ANAN 
treatment protected against the FS decrement and LV wall thinning observed in vivo 
and the LV developed pressure and þdP/dt decrements observed ex vivo. It is possible 
that ANAN’s protective effect may involve p38 mitogen-activated protein kinase and 
PKC and/or reducing myocardial ROS damage, but further research needs to be done 
investigating the mechanisms involved in ANAN’s protection against DOX 
cardiotoxicity. It may also be important to investigate ANAN’s protective effects 
beyond 5 days post DOX administration as well as its use in combination with other 
cardioprotective therapies. 
 
5.29 Cardioprotective effect of dexrazoxane in a rat model of 
myocardial infarction: anti-apoptosis and promoting angiogenesis 
The heart when subjected to persistent ischemia or myocardial infarction (MI), may 
lose considerable function and normal shape due to ischemia/reperfusion (I/R) injury. 
A key process in this I/R injury is attributed to the formation of reactive oxygen 
species (ROS). ROS, produced by partial reduction of oxygen during mitochondrial 
respiration especially under oxidative stress, containing singlet oxygen, superoxide 
radical (O2 −), hydrogen peroxide (H2O2) and hydroxyl radical (OH), are extremely 
reactive and highly toxic for tissues. Mitochondrial ROS burst can in turn promote 
myocyte apoptosis and heart failure. In the mitochondrial apoptosis pathway, Bcl-2 
family proteins are important mediators of pro-apoptotic (e.g. Bax and Bak) and anti-
apoptotic (e.g. Bcl-2 and Bcl-XL) regulations. Hearts of Bax knockout mice had 
improved contractile function, reduced mitochondrial damage and decreased infarct 
size after I/R injury compared with their wild type counterparts, implicating that Bax 
plays a critical role in myocyte apoptosis induced by I/R. In recent years, activation of 
endothelial progenitor cells (EPCs) has been considered as vital for the repair of 
various cardiovascular insults. Endothelial progenitor cells have the ability to 
differentiate into mature endothelial cells for the formation of new blood vessels in 
the ischemic or damaged tissues. Bone marrow-derived EPCs can effectively migrate 
and home to target areas under some physiological and pathophysiological 
stimulations. Intramyocardial transplantation of human EPCs in the rat model of MI 
significantly improved cardiac function and reduced apoptosis. Notably, clinical trials 
using intracoronary bone marrow-derived progenitor cells for treatment of acute MI 
have been performed and the results appeared promising. Dexrazoxane (ICRF-187, 
Zinecard®, DZR), belonging to a class of bis (2,6-dioxopiperazines), has been proven 
effective both in patients and animal models for reduction of doxorubicin (DOX)-
induced cardiotoxicity without affecting the antitumor activity. DZR was also used 
clinically as an antidote for alleviating tissue damage due to accidental anthracycline 
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extravasation. DOX-induced cardiotoxicity is cumulative, dose-dependent and 
essentially irreversible. The mechanism of DOX-induced cardiotoxicity is 
multifactorial and involves the induction of lipid peroxidation and generation of ROS. 
DZR could permeate the cell membrane and hydrolyze to its rings-opened metal-ion-
binding metabolite (ADR-925) with a structure similar to EDTA. ADR-925 could 
remove iron from the iron–DOX complex or bind free iron to decrease ROS 
formation. Ramu reported that DZR significantly inhibited I/R injury, decreased 
protein carbonylation and improved hemodynamic recovery by decreasing free radical 
formation in an isolated perfused rat heart. However, the effect of DZR on MI has not 
been well explored. In the present study, we tested the hypothesis that DZR might 
exert a cardioprotective effect in a rat model of MI and attempted to elucidate its 
underlying mechanism. 
Echocardiographic indices 
All echocardiographic parameters were similar among the 4 groups of animals at 
baseline. At 4 weeks post-MI, compromised heart function was observed in the MI 
animals compared with the SHAM group, as demonstrated in LVEDD (Pb0.001), 
LVESD (Pb0.001), FS (Pb0.001) and EF (Pb0.001). Treatment with DZR saw 
decreased LVEDD (P= 0.012) and LVESD (P= 0.009), and significant improvement 
in FS (P= 0.004) and EF (P= 0.004) compared with the MI group. MI+DZR animals 
also had a trend of increased CO (P= 0.062) compared with MI animals. 
 
5.30 Resveratrol treatment protects against doxorubicin-
induced cardiotoxicity by alleviating oxidative damage 
Resveratrol is a polyphenol phytoalexin that is found in a number of edible materials, 
such as grape skins and seeds, peanuts, mulberries and red wine. Resveratrol has been 
reported to have a wide range of pharmacological effects that include cardiovascular 
protection, neuroprotection, modulation of lipid metabolism, anti-carcinogenesis and 
anti-inflammatory effects. Resveratrol, when added to cultured cardiomyocytes in low 
micromolar concentrations, was shown to induce a number of endogenous 
antioxidants and phase 2 enzymes, including superoxide dismutase (SOD), catalase, 
glutathione (GSH), glutathione reductase (GR), glutathione S-transferase (GST) and 
NAD(P)- H:quinone oxidoreductase 1 (NQO1). Animal studies have shown that 
resveratrol reduces biliary cirrhosis-induced oxidative damage of the kidney and liver, 
as well as ischemia/reperfusion-induced tissue damage in the ovaries. An 
immunohistochemical study has shown that resveratrol attenuated the expression of 
CD86 in the glomerular endothelium and peritubular vessels in rats with 
ischemiareperfusion injury. In accordance with these studies, we have previously 
demonstrated that resveratrol improves stomach, kidney, bladder and lung damage in 
rat models of ulcer, ischemia/reperfusion and sepsis. Furthermore, we have also 
reported that resveratrol attenuates acetaminopheninduced hepatotoxicity and 
ifosfamide-induced nephrotoxicity. Based on these above-mentioned findings, in the 
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present study they aimed to investigate the possible beneficial activities of resveratrol 
against doxorubicin induced oxidative damage in the cardiac tissues of rats. 
Echocardiographic indices 
LV posterior wall thickness, LV end-diastolic and end-systolic dimensions, as well as 
relative wall thickness and percentage fractional shortening and ejection fraction were 
increased significantly (pB0.050.001) in the saline-treated rats with DOX 
cardiotoxicity. However, in the RVT-treated rats with DOX toxicity, these 
mesurements were significantly reduced (pB0.050.001). 
 
6. SUMMARY 
The recognition of cardiac problems related to the treatment of cancer is complex. 
The heterogeneity of the population makes comparison between and among groups 
difficult. Studies on sufficiently large populations are frequently not available, and the 
number of new agents used in the treatment of some diseases makes evaluation of 
large cohorts impossible. Some reported results are therefore fragmented, and 
prospective data on longterm survival, treatment strategies, and monitoring represents 
all too often expert opinion rather than firm and established dataderived certainty. 
Identifying patients who are at increased risk for cardiovascular problems associated 
with the cancer treatment, or who develop side effects following treatment is a major 
component of an evolving area often referred to cardio-oncology. Working together 
with oncologists, cardiologists can offer vital support to those who are the primarily 
clinicians treating cancer patients so that therapy can be optimized; the goal should be 
to maximize meaningful survival. Judicious scrutiny of the needs of these complex 
patients requires careful balance: excessive concern regarding potentially reversible 
cardiac issues may compromise the administration of highly beneficial anti-cancer 
therapies, while under-appreciation of cardiac risk may result in life-longcardiac 
concerns for a patient who has been cured of their cancer. Knowledge of the cardiac 
effects of anti-cancer agents balanced with knowledge regarding the natural history of 
the malignancy and the likelihood of tumour response offers such patients the greatest 
chance for long-term disease-free survival. 
Through observation of side effects caused by newly developed cancer therapeutics, 
some cardiovascular signalling pathways have become more clearly understood. It is 
postulated that the Neuregulin/ erbB2/HER2 signalling pathway, the target of several 
anti-cancer therapies, plays an important role in cardiovascular homeostasis, and 
studies are being conducted to evaluate the stimulation of this pathway to treat heart 
failure patients. 
Signalling inhibitors, chemotherapeutics, and combinations thereof are the subject of 
intense research and ongoing clinical trials in oncology. New cancer therapeutics will 
continue to target signalling cascades that may also be important for the survival and 
homeostasis of cardiovascular tissue. Cardiovascular side effects from these agents 
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should be expected because of their direct effect on signalling or the potential of 
additional nontargeted inhibitory effects. 
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